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Abstract
Chronic myeloid leukemia (CML) is a malignant stem cell disease characterised 
by an expansion of myeloid progenitor cells. These cells express a BCR/ABL 
fusion protein with constitutively activated tyrosine kinase activity, which causes 
a deregulation of apoptosis and cell cycle progression. In the pro-B BaF3 cell line, 
BCR/ABL has been shown to abrogate the IL-3 dependence to proliferate, but the 
signalling pathways activated by BCR/ABL and IL-3 to promote proliferation and 
survival are not yet well defined. In this study, BaF3 cells and a BaF3 cell line 
stably over-expressing BCR/ABL, BaF3-p210, were used to identify the 
downstream targets of BCR/ABL and IL-3. Both BCR/ABL and IL-3 were shown 
to induce the expression of cyclin D2 and inhibit the expression of the cell cycle 
inhibitor, p27^^^ This regulation was shown to be directly due to BCR/ABL, in 
haematopoietic cells, by two different approaches. First, using a BaF3 cell line 
(TonB210.1) where the BCR/ABL expression is inducible by doxycycline and 
second, by inhibiting the kinase activity of BCR/ABL with the Abl tyrosine 
kinase inhibitor STI571. In order to establish the functional significance of cyclin 
D2 and p27 '^^  ^ expression in response to IL-3 and BCR/ABL expression, the 
effects of ectopic expression of cyclin D2 and p27*^ ^^  on cell proliferation and 
survival were studied. The results demonstrate that both cyclin D2 and p27^^  ^
have a role in BaF3 cell proliferation and survival, as ectopic expression of cyclin 
D2 is sufficient to abolish the cell cycle arrest and apoptosis induced by IL-3 
withdrawal or BCR/ABL inactivation, while over-expression of p27^^  ^can cause 
cell cycle arrest and apoptosis in BaF3 cells. Next, the signal pathways triggered 
by BCR/ABL and IL-3 to regulate cell proliferation and apoptosis via cyclin D2 
and p27^ 'P^  were investigated. The PI 3-Kinase inhibitor LY294002 blocks the 
ability of BCR/ABL or IL-3 to induce cyclin D2 up-regulation and p27^^  ^down- 
regulation and inhibits BCR/ABL-induced entry in S phase. Ectopic expression of 
cyclin D2 was found to overcome the cell cycle arrest induced by inhibition of PI 
3-Kinase by LY294002. The results indicate that BCR/ABL and IL-3 target cyclin 
D2 and p27*^ *^  ^ to mediate cell cycle arrest and apoptosis through a pathway 
involving the phosphatidylinositol-3 kinase (PI 3-K).
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Chapter 1. INTRODUCTION
1.1 The eukaryotic cell cycle.
The production of two genetically identical daughters from a mother cell is known 
as the cell cycle and consists of three sequential processes: cell growth, DNA 
replication and cellular division. The cell cycle is classically divided into four 
phases (Figure 1.1), the most distinct being the S (Synthesis) phase where DNA 
replication occurs and the DNA content increases from 2N to 4N, and the cell- 
division phase M (Mitosis). M and S phases are separated by Gap phases, 01 
before DNA replication, during which the cell doubles its mass and duplicates all 
of its contents, and 02  before mitosis.
New daughter cells 
Mitosis
Synthesis
The Cell Cycle
Restriction point
Figure 1.1. The cell cycle and its phases.
Once a cell becomes committed to divide by passing the restriction point (R), in its cycle 
late in Gap 1 phase (Gl), it will replicate its DNA in the synthesis phase (S), proceed 
through the Gap 2 phase (G2), then divide in mitosis (M) and enter the G l phase of the 
next cycle.
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Multicellular organisms are composed of interacting communities of cells whose 
reproduction is tightly regulated to ensure that new cells are made only when they 
are needed. Therefore, it is essential to control the rate of cell proliferation and the 
rate of cell death. In order to do so the growth and division of each of its cells is 
carefully regulated and co-ordinated with its neighbours. The induction of 
proliferation requires the co-ordinated action of multiple intra- and extra-cellular 
signals.
1.1.1 The restriction point
In each division cycle, most cell types need not only to replicate their DNA, but 
also to grow and double their mass in order to maintain a constant size of the 
daughter cells. To achieve such precise co-ordination between duplicating their 
genome and increasing their size, cells are controlled by extracellular signals, for 
example, stimulation by mitogens.
The decision to either enter the S phase and divide, or remain in the Gl phase 
with an unduplicated genome takes place in mid-late Gl and is referred to as the 
restriction point (R). Whereas cells traversing the initial, pre-R, period of the Gl 
phase are strictly dependent on the presence of mitogenic stimuli, progression 
through R serves as a kind of molecular switch that results in a reduced 
requirement for growth factors in the post-R period of the Gl, S, G2 and M 
phases (Reed, 1997; Solvason et al., 2000). Once the restriction point is passed 
the cells are committed to the rest of the cell cycle. Thus, the restriction point (R) 
can be seen as a critical regulatory mechanism allowing a cell to monitor its 
environment and its own size, and an integrator and fundamental decision maker 
controlling the switch between alternative cellular fates such as cell division, 
temporal cell cycle arrest, quiescence and differentiation.
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A second decision point exists prior to the onset of mitosis, at the G2/M border. 
The main function of the G2/M pause is to ensure that DNA replication is 
complete and the replicated chromosomes are aligned and ready to be separated at 
mitosis.
Upstream, an intricate net of cell cycle regulators integrates the signals from 
various sources to ensure an accurate decision about whether or not to pass the 
restriction points.
1.1.2 Transcription Factor E2F
The regulation of eukaryotic gene expression during development, or in response 
to extracellular signals, is controlled primarily at the level of transcription. 
Transcription is regulated in a complex manner involving the co-ordinated action 
of the general or basal transcription machinery and specific transcription factors. 
E2F is a family of heterodimeric transcription factors each consisting of a member 
of the E2F family of proteins (E2F1-6) (Ginsberg et ah, 1994) together with one 
of the three known members of the DP family of co-activators (DPl-3). The E2F 
family includes five characterised members: E2F-1 through E2F-5, that largely act 
as transcriptional activators via a transactivation domain located at their C- 
terminus (La Thangue, 1996), and a sixth, isolated more recently, E2F-6 or EM A. 
The latter has been reported to repress transcription because it carries a DNA- 
binding, but not a transcriptional activation domain (Cartwright et al., 1998; 
Morkel et al., 1997). Each of the E2F and DP proteins contains a conserved DNA 
binding domain and dimérisation domain. The minimal DNA binding domain 
(DB) of E2Fs encompasses a stretch of basic residues, along with overlapping 
helix-loop-like and putative leucine-zipper-like domains. The basic region shows 
the highest level of sequence conservation between the first five members of the
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family, a fact which may explain why those E2F/DPs heterodimers are able to bind 
in vitro to a similar consensus binding site on DNA with no apparent differences in 
affinity. This minimal DB of E2Fs requires additional flanking regions to 
heterodimerise with DP proteins. The first flanking region is a short one 
immediately adjacent to DB containing a conserved heptad repeat with a 
hydrophobic residue. The second one covers a conserved domain termed “the 
marked box” with no predictable tertiary structure (lost et al., 1996; Lees et al., 
1993).
The E2F responsive genes can be divided into two groups:
1. a group that includes genes directly involved in the control of cell cycle 
progression, for instance E2F1, cdc2, cyclin A, Dl, E, c-myc [Stewart, 1995 
#171] andB-myb [Lam, 1995 #172], and
2. a group that contains genes coding for proteins involved in the actual DNA and 
chromatin biosynthesis an d that are co-ordinately up-regulated in late Gl, such 
as DHFR, DNA pol(a), TK, TS, PCNA, etc.
E2F binds to the promoters of these genes through binding sites related to the E2 
sites with the consensus sequence TTT(G/C)(G/C)CG(G/C) and causes either 
transcriptional activation as “free” E2F or repression in the form of “complexed” 
E2F.
The activity of E2F/DP heterodimers is subject to several levels of control. The 
expression of E2F-1 to E2F-3 is regulated at transcriptional levels in a cell cycle- 
dependent manner, being minimal in GO and maximal at the G 1/S transition 
(Moberg, et al., 1996; Slansky and Famham, 1996); in the case of the E2F-1 and 
E2F-2 gene promoters, this regulation is mediated by E2F-binding sites, which 
indicates an autoregulatory loop. Conversely E2F-4 and E2F-5 levels tend to 
remain constant throughout the cell cycle; however, their activity is critically 
dependent on regulated relocalisation to the nucleus upon interaction, either with a
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DP family member containing a nuclear localisation signal (NLS), or with a 
pocket protein (de la Luna et aL, 1996; Verona et al., 1997). The DP components 
show no significant fluctuations.
E2F/DP heterodimers interact with the pRB, p i07 and pl30 members of the 
pocket protein family. These proteins antagonise transcriptional activators of the 
E2F family with a specificity that is mainly determined by the E2F component 
(Moberg et al., 1996).
A further level of control of E2F proteins activity is represented by the 
ubiquitin/proteasome pathway. Targeting of E2F1 for ubiquitination occurs 
through the carboxyl-terminal region containing the pocket protein binding 
domains. Because of the overlapping nature of key pRB interaction sequences 
with ubiquitination targeting sequences of E2F1, pRB inhibits E2F1 
ubiquitination and turnover (Campanero and Flemington, 1997; Hateboer et al., 
1996).
1.1.3 Regulation by the pocket proteins
The three members of the pRB family (pRB, pl07 and pl30) are phosphoproteins, 
which are phosphorylated in a cell cycle dependent manner. The pRB family 
members can associate with E2F/DP heterodimers via their “pocket” domain . 
This association is controlled by the phosphorylation status of the pocket protein 
(Xiao et al., 1996). Multiple sites are phosphorylated in pRB, pl07 and pl30. The 
underphosphorylated forms of pRB, pl07 and p i30 are capable of binding and 
thereby inhibiting E2F/DP heterodimers. Although the pocket proteins are similar 
they interact with different E2F proteins. The pRB protein has been shown to bind 
preferentially to E2F1, E2F2 and E2F3, while pl07 and pl30 bind to E2F4 and 
E2F5 (Moberg et al., 1996). E2F6 has not been shown to bind any of the pocket
17
proteins. Phosphorylation of pocket proteins in mid-to-late Gl phase is 
functionally important because it is associated with the loss of the growth 
suppressive activities of the three pocket proteins. Indeed, following 
hyperphosphorylation of pRB, transcription of E2F-responsive genes and cell 
proliferation is initiated. Thus, pRB, pl07 and pl30 play a key role in the negative 
regulation of E2F activity.
The retinoblastoma tumour suppressor protein (pRB) is a rather important 
regulator of the Gl phase that is often disabled or lost, rather than overproduced, 
in cancer. The retinoblastoma gene, Rb, was identified over a decade ago as the 
first tumor suppressor (Friend et al., 1986; Cavenee et al., 1983). \ Although the 
gene was initially cloned as a result of its frequent mutation in the rare pediatric 
eye tumor, retinoblastoma, it is now thought to play a fundamental role in cellular 
regulation and is the target of tumorigenic mutations in many cell types. The 
tumor suppressor function of Rb was confirmed by its ability to inhibit the 
malignant phenotype when expressed in R6-tumor cells (Huang et al., 1988). 
Independent studies of oncogenes encoded by various small DNA tumor viruses 
provided the first clues that the pRB protein might be involved in the control of 
cellular proliferation. Expression of viral oncoproteins, such as adenovirus ElA, 
SV40 large T antigen or human papillomavirus E7 proteins, had been known to 
stimulate cell proliferation. Subsequently, these oncoproteins were found to bind 
directly to pRB (Dyson et al., 1989b; Hu et al., 1990; Ludlow et ah, 1989) and the 
regions needed for pRB association were found to overlap with the regions 
needed for oncogenic transformation, suggesting that viral proteins deregulated 
cell proliferation by binding and therefore inactivating pRB (Whyte et a/., 1988; 
DeCaprio et at., 1989; Munger et al, 1989).
Mutational studies of Rb suggested that the viral oncoproteins, above, targeted all 
the same functional domain of pRB consisting of two non-contiguous regions.
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referred to as “the pocket” (Ewen et al., 1992; Stirdivant et al., 1992). Domains A 
and B interact with each other along an extended interdomain interface to form 
the central “pocket”, which is critical to the tumor suppressor function of Rb 
(Chow and Dean, 1996). Viral oncoproteins contain an LXCXE motif that allows 
them to bind pRB at the B domain (Dyson et al., 1989b; Ludlow et al., 1989). 
However, domain A is required for domain B to assume an active conformation 
(Kim and Cho, 1997).
pRB operates through the modification of gene expression. pRB can repress 
transcription by at least two different mechanisms. First, it binds the 
transactivation domain of E2F blocking its ability to activate- transcription 
(Weintraub et al., 1992). Second, the pRB-E2F repressor complex that forms at 
promoters can actively repress transcription. pRB inhibits E2F by recruiting 
chromatin remodeling enzymes, including the HDACs (histone deacetylases), a 
family of at least seven different enzymes that remove acetyl groups from the tails 
of histone octamers, which appears to facilitate condensation of nucleosomes into 
chromatin (Brehm et al., 1998). This, inhibits gene expression by blocking access 
of transcription factors to the promoter. Whereas pRB requires sequences in the 
pocket and in the carboxy-terminal region to bind and inhibit E2F, the pocket 
alone is sufficient for active repression when pRB is tethered directly to the 
promoter (Sellers et al., 1995; Bremner et al., 1995; Weintraub et al, 1995). 
Progression of a cell through Gl and S phases requires inactivation of pRB by 
phosphorylation, as only unphosphorylated or hypophosphorylated forms are able 
to associate with their targets. The hypophosphorylated forms of pRB are thought 
to be active, capable of binding and thereby inhibiting E2F complexes. This form 
of pRB is present in GO and early and mid Gl phases. Under conditions favouring 
Gl this E2F-binding competent form of pRB is progressively phosphorylated 
until it is inactivated in the late Gl phase, resulting in derepression of E2F and
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other pRB-bound transcription factors, culminating in the activation of the 
transcription of S-phase genes (Figure 1.2) (Dyson, 1998; Weinberg, 1995). At 
this point, the cell is irreversibly commited to enter the S phase. pRB retains this 
hyperphosphorylated state throughout the remainder of the cell cycle until passage 
through mitosis, when the protein is quickly dephosphorylated. Removal of these 
phosphates appears to be carried out by a multimeric complex of protein 
phosphatase type 1 (PPl) and noncatalytic regulatory subunits at the completion 
of mitosis (Tamrakar et al., 2000). Thus, the hyperphosphorylated (inactive) forni 
predominates in proliferating cells, whereas the hypophosphorylated (active) form 
is generally more abundant in quiescent or differentiating cells.
A variety of physiological growth-inhibiting signals prevent pRB phosphorylation 
and so block cell cycle progression. These signals, which include TGF-|3, cyclic 
AMP and contact inhibition, activate the CKIs, that then associate with either a 
CDK or a cyclin-CDK complex, blocking its function, and therefore preventing 
pRB phosphorylation (discussed in the next section) (Hannon and Beach, 1994, 
Kato et al., 1994, Dulic et al., 1994).
pl07 and pl30 were originally identified as targets of the transforming domains 
of viral oncoproteins encoded by small DNA tumor viruses (Dyson et al., 1989a; 
Ewen et al., 1989). pl07 and pl30 are structurally very similar to pRB with the 
greatest homology lying in the pocket, hence they also can inhibit E2F-responsive 
promoters, recruit HDAC to the pocket, actively repress transcription and arrest 
the growth of cells when they are overexpressed (Paggi et al., 1996; Ferreira et 
al, 1998).
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There are significant differences between the pocket proteins: for example, the 
spacer sequences between domains A and B are longer in both pl07 and pl30 
than in the analogous region in pRB and present little homology. The p i07 and 
pl30 spacer regions include a high-affinity binding site for cyclin A/CDK2 and 
cyclin E/CDK2, which allows them to form stable complexes. In addition, pl07 
and p i30 each contain insertions within the B domain that are missing from pRB 
(Ewen et al., 1992; Hannon et al., 1993; Li et al., 1993).
Whilst the levels of pRB are quite constant during the cell cycle and in quiescent 
cells, levels of pl30 and pl07 change dramatically depending on the stage of the 
cell cycle. pl30 is highly expressed in both quiescent and differentiated cells, and 
its levels drop rapidly when quiescent cells are stimulated to enter the cell cycle 
(Cobrinik et al., 1993). In corttrast, p i07 levels are generally quite low in 
terminally differentiated cells and they rise when quiescent cells are stimulated to 
proliferate (Raschella et al., 1997; Shin et al., 1995).
Biochemical and genetic studies suggest that the pocket proteins have partially 
overlapping as well as distinct functions in cell cycle control and mouse 
development (Mulligan and Jacks, 1998). Mice lacking functional pRB died 
during embryogenesis, exhibiting defective erythropoiesis as well as excessive 
proliferation and cell death in the liver, lens and nervous system (Clarke et al., 
1992; Jacks et al., 1992; Lee et ah, 1992). Conversely, animals lacking pl07 or 
pl30 developed normally (Cobrinik et ah, 1996). However, the interbreeding of 
p i30 and pl07, Rb and pl07  or Rb and p i 30 mutant mouse strains has revealed 
significant functional overlap within the gene family. Mice deficient in p i30 and 
p i07 exhibit excessive chondrocyte proliferation, bone defects and rapid postnatal 
death (Cobrinik et ah, 1996). p i07 deficiency accelerates the Rb-/- embryonic 
lethality by 2 days (Lee et ah, 1996). These results suggest that, although having 
distinct roles in tumour suppresion and development, in the absence of a particular
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pocket protein some mechanisms of compensation exist by the remaining 
proteins.
1.1.4 Regulation of pRB activity through phosphorylation hy CDKs
Nearly all the phosphorylation sites identified in the pocket proteins fall within 
the consensus site of phosphorylation by Cyclin-Dependent Kinases (CDKs). 
Four of the CDKs function in cell cycle progression: CDC2 (CDKl), CDK2, 
CDK4 and CDK6. The activity of the CDKs is regulated by multiple mechanisms, 
including protein-protein interactions, protein degradation, transcriptional control, 
subcellular localisation, and multiple phosphorylations (Morgan, 1995; Solomon 
and Kaldis, 1998).
Cellular CDK levels tend to remain in constant excess throughout the cell cycle, 
but their catalytic activity requires activation by association with one or more of 
the 16 regulatory cyclin subunits and by their phosphorylation or 
dephosphorylation (Johnson and Walker, 1999; Pines, 1997; Sherr, 1993). Unlike 
CDKs, cyclins are regulated at the transcriptional level in a cell cycle-dependent 
way, as represented in Figure 1.2b, and therefore their expression is rate limiting 
for progression through the different stages of the cell cycle. Cyclin levels are also 
modulated by protein turnover. The ubiquitin-mediated proteolysis of cyclins 
ensures the irreversible and abrupt inactivation of the associated CDK. The cyclin 
family is divided into two main classes:
1. The 'Gl cyclins' include cyclins Dl-3, and E, and their accumulation is rate- 
limiting for progression from the Gl to S phase.
2. The 'mitotic or G2 cyclins', which include cyclin A and cyclin B, are involved 
in the control of G2/M transition and mitosis.
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Once assembled, the CDK/cyclin complex is activated by dephosphorylation of 
inhibitory sites (Thr-14 and Tyr-15) by the dual-specificity phosphatase CDC25, 
and phosphorylation on a single threonine residue (Thr-160 in human CDK2, Thr- 
161 in CDC2)) (Figure 1.3) (Morgan, 1995). The phosphorylation is mediated by 
the enzyme complex CDK-activating kinase (CAK), which is itself a multimeric 
enzyme composed of a CDK subunit (MO 15 or CDK7) and a cyclin partner (cyclin 
H) (Harper and Elledge, 1998). CAK appears to be present constantly during the 
cell cycle, suggesting that mitogenic signals are not required for its induction, but 
certain CDK inhibitors can prevent CAK from accessing its substrates, thereby 
preventing the formation of enzymatically active cyclin/CDK complexes (Kato et 
ah, 1994). It has been proposed that phosphorylation of the Thr residue by CAK 
induces a conformational change within the CDK/cyclin complex to fully expose 
the catalytic cleft in order that substrates may bind (Jeffrey et al., 1995; Russo et 
al., 1996).
The first cyclin/CDK to be activated after growth factor stimulation contains a D- 
type cyclin (Dl, D2, D3) and either CDK4 or CDK6 (Figure 1.2a), and has a 
distinct substrate preference for the retinoblastoma protein (RB). Unlike other 
members of the cyclin family, cyclins D l, D2 and D3 have unique cell- and tissue- 
specific patterns of expression (Sherr, 1993). After mitogen withdrawal, D-type 
cyclins are rapidly degraded. Cyclin E is synthesised later than D-type cyclins, with 
expression levels peaking at the Gl/S boundary, and associates with CDK2; the 
resultant complex has a broader specificity, phosphorylating histone HI, pRB and 
the CDK inhibitor p27^P\
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Figure 1.3. Model for CDK regulation. The activation of the CDKs is determined by their 
post-translational modifications and by the association with a cyclin.
Upon association with a cyclin, CDK is activated by phosphorylation by the CDK-activating 
kinase (CAK) on a single residue. The catalytic activity is inhibited by further phosphorylation 
by Wee 1 on two residues; déphosphorylation by CDC25 and removal of the cyclin subunit; or 
binding by a CDK inhiWtor (CKI) (dashed arrows)
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Once the cells enter into the S phase, cyclin E is degraded and CDK2 forms 
complexes with cyclin A. The last complex to be formed comprises CDC2 and 
cyclin B and triggers the entry into mitosis. In conclusion, D-type cyclins are 
responsible, together with their partner kinases CDK4/6, for the phosphorylation 
of pocket proteins in Gl, resulting in abrogation of the interaction of the pocket 
proteins with E2F/DP complexes. Upregulation of cyclin D seems to be more 
important for the G 1/S transition, whereas cyclin E seems more important for S 
phase entry. Cyclin A helps to maintain pRB in hyperphosphorylated forms until 
exit from mitosis.
Both the D-type cyclins and their partner kinases, CDK4/6, have proto-oncogenic 
properties, and their activity is carefully regulated at multiple levels. Four major 
mechanisms have been identified to inactivate CDK-cyclin complexes:
1. Phosphorylation at two sites near the amino terminus (Thr-14 and Tyr-15 in 
human CDC2). Phosphorylation of these residues is important for the control 
of CDC2 activity and abrupt dephosphorylation at these sites occurs at 
mitosis.
2. Removal of cyclin.
3. Dephosphorylation of the Thr 160/161 residue, by the phosphatase CDC25.
4. Inhibition by inhibitory subunits.
1.1.5 Regulation of CDK activity during the ceil cycle.
The catalytic activity of the cyclin/CDK complexes is controlled by several 
mechanisms, one of which involves a family of low molecular weight inhibitors. 
The CDK inhibitors (CKIs) represent a growing superfamily of negative 
regulators that help to mediate temporary arrest or permanent withdrawal from the
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cell cycle, either in response to anti-mitogenic or genotoxic stimuli, or as part of 
programmes of terminal differentiation. Thus, they play a role in development, 
checkpoint control and tumour suppression. In mammalian cells, two classes of 
CKIs have been identified: the INK4 (inhibitors of CDK4) class and the CIP/KIP 
class (Sherr and Roberts, 1999). The activity of members of the INK4 subfamily, 
pl5iNK4b (Hannon and Beach, 1994), pl6^ *^ "^  ^ (Serrano et al, 1993), pfg^^c 
pl9iNK4d^  is particularly linked with pRB as their ability to inhibit the cell cycle 
depends on functional pRB (Lukas et a l, 1995; Medema et a l, 1995; Sherr and 
Roberts, 1995). They specifically inhibit the CDK4/6 dependent-kinases (Roussel, 
1999). plb^"*^ has been shown to play an important role in cellular senescence, 
and its loss results in cell immortalisation (Serrano et al, 1996).
The members of the CIP/KIP subfamily of CKIs, p21^'^\ p27^ '^  ^ and p57^^ ,^ 
contain characterisitic motifs within their amino-terminal moieties that enable 
them to bind and therefore inhibit most cyclin-CDK complexes (Harper, 1997). 
p21^ 'P^  was the first mammalian CKI to be identified (Harper et a l, 1993; Xiong 
et a l, 1993). It is well established that p21 '^^  ^ consists of a least two functional 
domains that bind to CDK/cyclins and proliferating cell nuclear antigen (PCNA) 
(Podust et a l, 1995; Xiong et a l, 1992; Zhang et a l, 1993). In addition to 
interacting with the CDK, the independent binding of p21^ 'P^  to PCNA seems to 
block its ability to activate DNA pol Ô, inhibiting DNA replication (Chen et a l, 
1995; Nakanishi et a l, 1995). p21 '^^  ^ is also involved in the p53-mediated Gl 
arrest cellular response to DNA damage (Sherr and Roberts, 1995). Mice 
nullizygous for p21 '^''  ^ develop normally, but have a more relaxed response of 
their cells to DNA damage, consistent with a role of p21 '^^  ^ in G l phase 
checkpoint control (Brugarolas et al, 1995; Ando et al, 2001). 
p2 7 Kipi|s a widely expressed inhibitor of the essential cell cycle kinase CDK2, 
which regulates entry into the S phase (Sherr and Roberts, 1999). p27^^  ^was first
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identified as an inhibitor of cyclin E/CDK2 (Polyak et al., 1994; Toyoshima and 
Hunter, 1994). High levels of inhibit the activity of the CDK2/cyclin E 
complex, prevent phosphorylation of critical target molecules for initiation of the 
S phase, including pRB, and induce an arrest in Gl (Hsieh et al, 2000). In normal 
cells, progression through Gl/S phase requires that p27^^  ^be displaced from 
CDK2, either by sequestration in cyclin D/CDK4 complexes, or by down- 
regulation of the protein through multiple mechanisms. Many antiproliferative 
signals lead to p27^^  ^accumulation, including mitogen/cytokine withdrawal, cell­
cell contact and agents such as cAMP and rapamycin (Sherr and Roberts, 1995). 
The role of p27^*’^ seems to be very important in regulating cell proliferation as 
the p27^^^ knockout mouse exhibits gigantism, female sterility and increased 
tumourigenesis (Eero et a l, 1996; Nakayama et al., 1996).
The cellular threshold levels of CKIs appear to be carefully controlled by a variety 
of mechanisms, including transcriptional regulation, post-transcriptional 
regulation, sequestration in cellular compartments and degradation. For p21^'^\ a 
major mode of regulation is transcriptional, induced by p53, a transcriptional 
regulator that mediates cell-cycle arrest following DNA damage and in 
senescence (Dulic et al., 1994). Transcriptional control may also be important for 
p2^ iNK4b^  whose expression in human kératinocytes is greatly enhanced by 
treatment with the negative growth factor TGF-P (Hannon and Beach, 1994). 
p2 7 Kipi expression has been shown to be regulated at various levels. It occurs at 
both transcriptional and translational levels. p27^^^ may be degraded by the 
ubiquitin/proteasome pathway (Esposito et al, 1997; Hengst and Reed, 1996). 
p2 7 Kipi jg also regulated by phosphorylation (Vlach et a l, 1997). The most 
recently proposed mechanism of p27^'^^ regulation is subcellular 
compartmentalisation (Orend et al, 1998). p27 '^^  ^appears to interact with its 
targets in the cell nucleus, and mislocalisation of p27^^  ^in the cytoplasm might
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inactivate by sequestering it away from the relevant cellular targets
(Depoortere et al., 2000; Liu et al., 2000). These multiple control mechanisms 
seem justified given that elevated levels of CKIs from either subfamily can cause 
GI phase arrest, suggesting that these integral elements of the cell cycle 
machinery exert a significant influence on the Gl phase checkpoint control.
1.1.6. Cell cycle arrest and apoptosis
Control mechanisms are required to guarantee that all the necessary preparations 
are completed in the correct sequence before cell division occurs. Of the processes 
that must be given adequate time for completion, DNA replication is one of the 
most critical (Hartwell and Weinert, 1989; Murray, 1992). DNA damage can 
occur by exposure to mutagens such as ultraviolet light, x-rays, chemotherapeutic 
drugs or increased levels of oxidants within the cell, or due to replication errors. 
To protect themselves from accumulating DNA damage, mammalian cells possess 
mechanisms which ensure that deleterious mutations are removed from the 
population.
The first one is the arrest in Gl phase of the cell cycle. In early G1 phase, the 
CDKs of the cell-cycle control system are reduced to an inactive state by several 
molecular braking mechanisms. In the absence of the appropriate signals to 
proliferate, these brakes are held in place and CDK inhibition is maintained, 
prolonging Gl phase. When proliferation signals appear, the brakes are released 
and CDK activation occurs, leading to a new round of cell division. However, 
damaged cells reversibly arrest their cycle at checkpoints, allowing time for the 
necessary DNA repair.
The second mechanism is referred to as apoptosis. If the damage is too great, the 
cell may activate apoptotic pathways, leading to its death. Non-necrotic cell death
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has been known of for at least fifty years (Glucksmann, 1965), and in 1972, the 
term apoptosis was coined to describe this form of programmed cell death (Kerr et 
al., 1972). Apoptosis describes the process by which cells are removed under 
normal conditions when they reach the end of their life span, are damaged, or 
superfluous. Morphologically, in cells undergoing apoptosis, there is ruffling and 
condensation of the plasma and nuclear membranes, and subsequently, 
aggregation of nuclear chromatin (Lowe and Lin, 2000). The cell shrinks and then 
fragments into a cluster of membrane-enclosed “apoptotic bodies” that are rapidly 
ingested by adjacent macrophages (Wyllie et al., 1980). The hallmark of the end 
stage of apoptosis is the endonuclease cleavage of DNA in the intemucleosomal 
linker regions, yielding 180 base-pair fragments. Apoptosis is a general tissue 
phenomenon necessary for development and homeostasis: elimination of 
redundant cells during embryogenesis, cell atrophy upon endocrine withdrawal or 
loss of essential growth factors or cytokines, tissue remodelling and repair, and 
removal of cells that have sustained genotoxic damage.
Defects in these processes can lead to excess cell proliferation and, under some 
conditions, cause cancer.
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1.2 Haematopoiesis.
The production of mature blood cells, haematopoiesis, occurs predominantly in 
the adult bone marrow. Differentiation of a limited population of self-renewing 
pluripotent stem cells results in the generation of distinct lineage-committed 
myeloid or lymphoid progenitor cells (Figure 1.4); these cells can be further 
induced to differentiate. The myeloid progenitor is the precursor of the 
granulocytes, monocytes, megakaryocytes and erythrocytes, whilst the common 
lymphoid progenitor gives rise to the lymphocytes, which are responsible for the 
specificity of the immunoresponse. There are two major types of lymphocytes: B 
lymphocytes, which when activated differentiate into plasma cells that secrete 
antibodies, and T lymphocytes, which exert cell-mediated responses.
1.2.1 Regulation of haematopoiesis.
Early research in haematopoiesis demonstrated that haematopoietic cells could not 
be maintained in culture unless certain viability factors or viability factor- 
producing cells were provided (Sachs, 1987; Sachs, 1988; Sachs, 1996). Cell 
culture supernatants were used to isolate, characterise and clone the genes coding 
for a large family of soluble polypeptides referred to as haematopoietic cytokines. 
Cytokines are a unique family of growth factors able to strictly control the 
proliferation, differentiation, survival and effector functions of haematopoietic 
progenitor cells. Secreted primarily from leukocytes, cytokines stimulate both the 
humoral and cellular immune responses, as well as the activation of phagocytic 
cells. Cytokines that are secreted from lymphocytes are termed lymphokines, 
whereas those secreted by monocytes or macrophages are termed monokines.
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Figure 1.4. Schematic representation of haematopoiesis
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Originally, the cytokines were named according to their function (like the T cell 
growth factor, now called IL-2), but then the pleotropy of cytokines was observed, 
making function specific names confusing. After more and more cytokines were 
identified, and in order to avoid confusion, immunologists started naming some of 
the lymphokines 'interleukins' (ILs), since they are not only secreted by 
leukocytes but also able to affect the cellular responses of leukocytes, and 
numbering them as they were found. A sample of some cytokines and their 
functions is given in Table 1, below.
Colony stimulating factors (CSFs) are cytokines that stimulate the proliferation of 
specific pluripotent stem cells of the bone marrow in adults. Granulocyte-CSF (G- 
CSF) is specific for proliferative effects on cells of the granulocyte lineage. 
Macrophage-CSF (M-CSF) is specific for cells of the macrophage lineage. 
Granulocyte-macrophage-CSF (GM-CSF) has proliferative effects on both classes 
of lymphoid cells. Erythropoietin (Epo) is also considered a CSF as well as a 
growth factor, since it stimulates the proliferation of erythrocyte colony-forming 
units.
Other sub-groups of the cytokines are the tumour necrosis factors (TNFs), 
Interferons (IFNs) and the Transforming Growth Factors (TGFs).
Cytokines bind to their cognate receptors and mediate intracellular signal 
transduction events that result in the modulation of gene expression (Mannoni, 
1993). One of the characteristic features of cytokines is their functional 
pleiotropy, i.e. a particular cytokine can exhibit a wide variety of biological 
functions on various tissues and cells. (Reddy et ah, 2000). Cytokines also 
function in a redundant manner and several different cytokines can exert similar 
and overlapping functions on the same cell type. Such functional pleiotropy and 
redundancy, initially thought to be a consequence of the structural characteristics
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Cytokine Principle Source Principle activities
IL-1 Macrophage and other 
antigen presenting cells 
(APCs)
T,B cell activation, fever, 
inflammation, acute phase response, 
haematopoiesis
IL-2 T cells T cell proliferation
IL-3 T cells Growth of haematopoietic progenitor 
cells
IL-4 T cells B cell growth and differentiation
IL-5 T cells B cell, eosinophil growth
IL-6 Macrophages, T cells B cell stimulation, inflammation
IL-7 Stromal cells Early B and T cell differentiation
IL-8 Macrophages Neutrophil (PMN) attraction
IL-9 T cells Mitogen
IL-10 T cells Inhibits Thl cytokine production, B cell 
proliferation, antibody production, 
cellular immunity suppression, mast 
cell growth
IL-11 Bone marrow stroma Synergisitc haematopoietic and 
thrombopoietic effects
BL-12 AFC Stimulates T, NK cells
IL-13 T cells B cell growth and differentiation
IL-14 Dendritic cells,T cells B cell memory
IL-15 T cells T cell proliferation
IFN-a Macrophages, neutrophils 
and some somatic cells
Anti-viral
IFN-P Macrophages, neutrophils 
and some somatic cells
Anti-viral
IFN-y T,NK cells Inflammation, macrophage activation
TGF-P Macrophages, lymphocytes Depends on target
TNF-a Macrophage Inflammation; tumor killing
TNF-P T cells Inflammation; tumor killing, enhance 
phagocytosis
Table 1. Properties of some Cytokines.
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of cytokines themselves, is now regarded to be a reflection of similarities and 
differences in the proteins interacting with cytokine receptors.
Most cytokine receptors consist of a multisubunit protein complex: a unique and 
specific ligand binding subunit, and a ligand transducing subunit, which may be 
structurally similar to other members of the cytokine receptor superfamily (Onishi 
et al., 1998). The signal transducing subunit is responsible for propagation of the 
signals to downstream target proteins upon cytokine binding. It recruits 
cytoplasmic proteins, which leads to changes in protein-protein interactions as 
well as changes in the phosphorylation status of several proteins (Stahl and 
Yancopoulos, 1993). ' \
The cytokine receptor family has been sub-divided based on the characteristic 
structural motifs in their extracellular domains. The main sub-types include:
1 The gpl30 family, as well as receptors for IL-6, IL-11, cardiotropin-1 (CT), 
ciliary neurotrophic factor (CNTF) and oncostatin M (Sanchez-Cuenca et al., 
1999).
2 The IL-2 receptor family, comprising the receptors for IL-2, IL-7, IL-9 and 
IL-15.
3 The growth hormone (GH) family, including receptors for growth hormone, 
prolactin, erythropoietin, GCSF and thrombopoietin.
4 The interferon (IFN) family, together with the IFN-a and -y and the EL-10 
receptor.
5 The gpl40 family, including the receptors for EL-3, EL-5 and GM-CSF.
The network of growth stimulatory and inhibitory cytokines that regulates the 
proliferation of haematopoietic cells acts primarily in GO/Gl. After each round of 
replication of specific lineage cells, exposure to an adequate level of lineage-
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specific growth factors is required, without which the cells rapidly arrest in Gl 
and undergo apoptosis, a genetic program of cellular self-destruction (Dexter and 
Hey worth, 1994). Apoptosis is widely recognised to play a role in both the 
physiology and pathology of the immune system as crucial as cell division or 
differentiation (Allen et al, 1993). For example, apoptosis is a fundamental 
feature during the development of the lymphocyte repertoire, being intimately 
involved in the negative and positive selection of T and B lymphocytes bearing 
antigen receptors. For these populations, dysregulation of the selection 
mechanisms could result in a number of disease states: deletion of clones essential 
to the immune response may lead to immunodeficiency; production of 
lymphocytes bearing antigen receptor for self would encourage autoimmunity, 
while overproduction of lymphocyte clones could predispose to malignancy 
(Squier et a l, 1995; Straus et a l, 2001). There are two classes of interaction by 
which apoptosis can be induced. First, by a particular stimulus, such as 
engagement of the T-cell receptor or the Fas/Apo-1 antigen (Mapara et al, 1993; 
Trauth et a l, 1989). Second, from removal of a stimulus, such as Interleukins, 
which normally suppresses apoptosis (Duke and Cohen, 1986; Williams et a l, 
1990).
In addition to soluble signalling molecules, specific intracellular contacts regulate 
the haematopoiesis. However, the role of the cytokines is crucial in 
haematopoiesis. Myeloid malignancies are often characterised by the arrest of 
maturation and cytokine-independent proliferation of the myeloid progenitors.
36
1.2.2 Interleukin-3 (IL-3) and its receptor (IL-3R)
Interleukins are growth factors targeted to cells of haematopoietic origin. The list 
of identified interleukins grows continuously with the total number of individual 
activities now at 23 (Oppmann et al, 2000; Wiekowski et al., 2001).
The cytokine interleukin-3 (IL-3), also referred as multi-CSF, is a 28kDa 
glycoprotein secreted by CD4^ T cells. IL-3 is an important regulator of 
haematopoiesis modulating the proliferation, differentiation and survival of 
various haematopoietic cell lineages and their precursors, including stem cells, 
neutrophils, eosinophils, macrophages, etc. (Pierce, 1989).
The IL-3 receptor (IL-3R) consists of an a-subunit of 60-70 kDa and a P-subunit 
of 130-140 kDa (Miyajima et a l, 1992). Both subunits contain the extracellular 
conserved motifs found in the cytokine receptor superfamily, whilst the 
cytoplasmic domains show little similarity with other cytokine receptors and lack 
detectable catalytic domains, such as the tyrosine kinase domains. However, 
previous evidence suggests that IL3 signal transduction involves tyrosine 
phosphorylation (Kanakura et al., 1990).
The common beta subunit (P^ . ) on the IL-3 receptor is shared by the receptors for 
IL-5 and GM-CSF, and its cytoplasmic domain can be divided into two distinctive 
functional domains: a membrane proximal portion responsible for the binding to 
multiple signal-transducing proteins such as Janus kinases (JAKs), signal 
transducers and activators of transcription (STATs), phosphatidylinositol-3 kinase 
(PI 3-K), c-Src and Vav (Woodcock et ah, 1996; Yoshimura et ah, 1996), and a 
membrane distal domain involved in the growth inhibition that can be induced by 
some of the cytokines. The a  chain confers the specificity of the binding to a 
cytokine through its extracellular ligand-binding domain.
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Three different pathways (Figure 1.5) have been reported to be predominantly
responsible for most of the cellular processes induced by IL-3:
1. JAK/STAT. This important pathway in haematopoietic growth factor 
signalling involves activation of the non-receptor Janus family kinases 
(JAKs), consisting of four members: JAKl, JAK2, JAK3 and TYK2. STATs 
proteins are a unique family of transcription factors initially identified in 
interferon signalling. Upon cytokine binding, the JAKs are activated by trans­
phosphorylation of two-receptor-bound JAK molecules and phosphorylate a 
number of substrates including the cytokine receptor. The cytokine receptor 
provides docking sites for a variety of Src homology 2 (SH-2) domain- 
containing proteins, including the STATs. Once phosphorylated the STATs 
dimerise, migrate into the nucleus and regulate gene transcription (Ihle et al.,
1998). IL-3 activation of haematopoietic cells appears to result predominantly 
in the activation of JAK-2, although JAK-1 and TYK-2 have also been found 
to be activated in certain cell systems (Chaturvedi et a l, 1997; Liu et a l,
1999). Similarly, although activation of ST ATI, STAT3 and STAT6 has been 
observed, STAT5 seems to be the most predominant STAT activated by the 
EL-3 receptor (Chin et al, 1996). However, over the past few years, increasing 
evidence has accumulated which indicates that at least some of the STAT 
protein activation may be mediated by members of the Src family following 
cytokine stimulation (Reddy et a l, 2000). This pathway seems to play a 
decisive role in cell differentiation (Parganas et a l, 1998; Ihle, 1995) and to 
contribute to survival to a lesser extent.
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Figure 1.5. Schematic representation of signal transduction pathways activated 
by IL-3.
Receptors activation leads to the activation of multiple cytoplasmic 
signalling molecules (oval boxes). These pathways eventually lead to 
altered gene transcription (rectangles) or directly contribute to function, 
such as differentiation, proliferation and survival. Dashed lines represent 
connections to be demonstrated (from de Groot RP et al., 2000)
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2. MAPKinase. Activation of this pathway is a common event upon stimulation 
of haematopoieitc growth factor receptors, and in cells transformed with 
oncogenic tyrosine kinases. Ras belongs to the large Ras superfamily of 
monomeric GTPases. Downstream effectors of Ras include serine and 
threonine kinases, such as Raf or extracellular signal-regulated kinase (ERK). 
The activation of Ras can be strictly regulated by the GDP/GTP nucleotide 
exchange factor SOS or Ras-GAP, a Ras/GTPase activating protein. A critical 
event in Ras activation is the relocalisation of SOS through the adapter 
proteins GRB2 and She. Activation of the MAPKinase ERK by IL-3 is 
expected to occur through activation of Ras and c-Raf (Coffer et a l, 1998; 
Satoh et a l, 1991). This activation will result in enhanced transcription of c- 
fos and c-jun and might contribute to IL-3-induced proliferation (de Groot et 
al, 1997; Terada et a l, 1997). Dominant-negative Ras inhibited the IL-3 
induced activation of Raf and ERK and abolished almost completely c-fos 
expression, but IL-3 dependent proliferation and viability were not altered. In 
contrast, a constitutively active Ras mutant prevented unstimulated IL-3 
dependent cells from apoptosis (Terada et a l, 1995). Studies suggest that IL- 
3-induced Ras-Raf-ERK activation plays an important role targeting the anti- 
apoptotic proteins bcl-2 and c-Myc (Kinoshita et a l, 1995).
3. PI 3-Kinase. Phosphatidylinositol-3 kinase is a heterodimer composed of an 
85 kDa regulatory subunit and a 110 kDa catalytic subunit, and is found in 
cellular complexes with activated growth factor receptors and oncogene 
protein tyrosine kinases. It catalyses the addition of a phosphate molecule 
specifically to the 3-position of the inositol ring of phosphoinositides, 
producing mainly PI-(3,4)-bisphosphate and PI-(3,4,5)-triphosphate, which 
function as second messengers (Rameh and Cantley, 1999). A role for PI 3-K
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in signal transduction pathways and biological functions, such as reduced 
apoptosis, mitogenesis, integrin activation and membrane traffic have been 
established for various systems (Klippel et al., 1996).
One of the major functions of IL-3 is the inhibition of apoptosis in the target 
cells. Recent advances suggest that the PI 3-K/AKT pathway contributes to 
survival induced by IL-3 (Coffer et al., 1998). Particularly, the availability of 
specific inhibitors, such as LY294002 and wortmannin opened the way to 
more extensive studies on this pathway. Indeed, treatment with both inhibitors 
on BaF3 and 32D3 cells completely inhibited cellular survival induced by IL-
3. Moreover, overexpression of active PKB/AKT, a downstream effector of 
the PI 3-K, results in IL-3-independent survival of these cells and promotes 
the expression of the anti-apoptotic c-myc and bcl-2 genes (Ahmed et al., 
1997; Songyang et at., 1997). A major target for PKB/AKT was shown to be 
the pro-apoptotic bcl-2 family member BAD, which is phosphorylated by 
PKB/AKT at the same residues that are phosphorylated in response to IL-3 
and that block its pro-apoptotic activity (Datta et al, 1997; del Peso et al.,
1997).
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1.3 Chronic myelogenous leukemia (CML)
Whereas the growth of normal cells is carefully regulated to meet the needs of the 
whole organism, one of the defining features of cancer cells is that they respond 
abnormally to the control mechanisms that regulate the division of normal cells. 
As a result cancer cells replicate continuously, ultimately interfering with the 
function of normal tissues. This ability is often conferred by altered genes that 
mimic the growth factor exposed state or suppress apoptosis and hence lead to 
unregulated proliferation. This set of oncogenes are mutant versions of normal 
cellular “proto-oncogenes”. Proto-oncogenes regulate positively cellular growth in 
response to stimulatory signals. Once activated in cancer, proto-oncogenes are 
termed oncogenes, and act in a dominant fashion through a gain of function to 
promote cell growth. The process of activation of proto-oncogenes to oncogenes 
can include retroviral transduction or retroviral integration, point mutations, 
insertion mutations, gene amplification, chromosomal translocation and/or 
protein-protein interactions. Examples .of oncogenes include the Ras family 
(Radhika and Dhanasekaran, 2001; Wyllie et ah, 1987), the Myc transcription 
factor (Lee and Reddy, 1999) and the non-receptor tyrosine-specific protein 
kinase ABL. In contrast, tumor suppressor genes repress cell growth in response 
to inhibitory signals. Defects in tumour suppressor genes involve the loss of gene 
function by mutation or inactivation. Some well-known tumour suppressors are 
the INK4 CDKIs (Sherr and Roberts, 1999) and Rb (Dyson, 1998). The 
identification of the abnormalities that result in cancerous growth can lead to the 
understanding of the mechanisms that control normal growth and development. 
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder 
characterised by a clonal expansion of progenitor cells. As a result, patients have 
high leukocyte counts due to accumulation in the blood of immature cells of the 
granulocytic lineage. The annual incidence is approximately one to two cases per
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100,000 per year, increases with age, with a male:female ratio of 1.4:1, and 
constitutes 14% of all leukemias (Lee, 2000).
CML progresses through three distinct phases: the stable or chronic phase, the 
accelerated phase and blast crisis. The chronic phase is characterised by massive 
expansion of myeloid cells, which maintain normal maturation. Patients with 
chronic phase CML have effective immune systems and generally feel well for 
prolonged periods. Common symptoms are often mild and include fatigue, weight 
loss, body aches and discomfort caused by splenomegaly (Lee, 2000). In the later 
phases, leukemic cells lose their capacity to terminally differentiate; the result is 
an acute leukemia, which is highly refractory to therapy.
1.3.1 BCR/ABL
The cytogenetic hallmark of all phases of CML and a subset of cases of acute 
lymphoblastic leukemia (ALL) is the Philadelphia (Ph) chromosome, designated 
after the city where the abnormality was first recorded. The discovery of the 
Philadelphia chromosome in 1960, as the first consistent chromosomal 
abnormality associated with a specific type of leukemia, was a breakthrough in 
cancer biology.
The Ph chromosome is a shortened chromosome 22 that results from a reciprocal 
translocation between the long arms of chromosomes 9 and 22. The molecular 
consequence of this translocation is the fusion of the c-Abl oncogene from 
chromosome 9 with sequences from chromosome 22, the breakpoint cluster 
region (bcr), giving rise to a fused bcr/abl gene. Depending on the site of the 
breakpoint in bcr, various different fusion proteins are produced: p i85 (185 kDa), 
p210 (210 kDa), or rarely p230. All three BCR/ABL fusion proteins exhibit 
deregulated tyrosine kinase activity compared with the native ABL protein and
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are associated with malignant transformation. Tyrosine kinases are enzymes that 
transfer phosphate from ATP to tyrosine residues on substrate proteins that in turn 
regulate cellular processes, such as proliferation, differentiation, and survival. 
Therefore it is not surprising that deregulated tyrosine kinase activity has a central 
role in malignant transformation. The p210 protein is seen in 95% of patients with 
CML and up to 20% of adult patients with de novo ALL (acute lymphocytic 
leukemia); the p i85 form is seen in approximately 10% of patients with ALL and 
in the majority of pediatric patients with Ph+ ALL (5% of all pediatric ALL 
cases), p230BCR/ABL is associated with the very rare Philadelphia chromosome 
(Ph)-positive chronic neutrophilic leukemia (Mauro and Druker, 20Ô1).
The role of BCR/ABL in inducing CML has been shown using a number of 
different systems: transgenic murine model systems have established its ability to 
induce leukemia and retroviral transduction of BCR/ABL into murine bone 
marrow has reproduced a CML-like myeloproliferative disorder (Daley et al. 
1990).
1.3.1.1 c-Abl
The c-Abl gene is a member of the family of non-receptor tyrosine kinases 
consisting of the normal cellular proteins c-Abl and Arg. c-Abl is the cellular 
homologue of the transforming protein found in the Abelson murine leukemia 
virus (v-Abl).
The Abelson murine leukemia virus was first isolated from a mouse that 
developed a pre-B lymphoma following introduction of Moloney murine 
leukemia virus (Abelson and Rabstein, 1970). The viral genome was found to 
contain viral gag sequences and a novel gene, later identified as the c-terminus of 
murine c-Abl.
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C-Abl comprises two alternative first exons, la  and lb, and common exons 2-11 
(Holyoake, 2001). Human ABL is a ubiquitously expressed 145 kDa protein with 
2 isoforms arising from alternative splicing of the first exon and contains several 
function domains: SH3, SH2, SHI domains in the N-terminal region, a nuclear 
localisation signal (NLS), a proline-rich region capable of associating with SH3- 
containing proteins, a sequence-independent DNA-binding domain (DB), and an 
actin-binding domain (AB) (Figure 1.6) (Chung and Wong, 1995; Zou and 
Calame, 1999). c-Abl appears to have a major role in regulating cell cycle 
progression. In the nucleus in quiescent cells, the Abl activity is inhibited by 
binding a complex involving the retinoblastoma (Rb) protein. However, as cells 
progress from the Gl phase to the S phase, pRB is phosphorylated, dissociates 
from Abl, which then becomes activated and is phosphorylated by CDC2 kinases, 
with subsequent effects on transcription and progression to S phase (Wang, 2000). 
c-Abl activity is positively regulated by DNA damage signals. Cells lacking c-Abl 
can activate cell cycle checkpoints and DNA repair, but show defects in apoptosis, 
correlated with a defect in the induction and activation of p73. c-Abl knockout 
mice have perinatal mortality and display facial abnormalities. Also, the spleen is 
abnormal, and development of T cell, as well as B cell progenitors, in the bone 
marrow is reduced (Tybulewicz et al, 1991). Thus, c-Abl is a potent transforming 
oncoprotein, and understanding its immediate substrates and final targets will help 
in understanding the processes required for malignant transformation.
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1.3.1.2 BCR gene and protein
The break point cluster region (BCR) gene on the chromosome 22 comprises 23 
exons in a region of 135 kb. Gene expression results in transcription into two 
mRNAs, of 4.5 kb and 7 kb, both of which are translated into a 160 kDa protein. 
BCR is ubiquitously expressed, with the highest levels in brain and 
haematopoietic tissues, and it is localised in the cytoplasm. The BCR protein has 
multiple functional domains, the most critical of which is the dimérisation domain 
(DD) at the N-terminus, responsible for the homotetramerisation of the BCR/ABL 
molecule and necessary for its transforming potential (Tauchi et al, 1997). This 
domain is followed by a unique Serine-Threonine kinase domain, including at 
least three SH2 binding sites and particularly a tyrosine (TYR 177), the 
autophosphorylation of which is necessary for binding to ORB2 and activation of 
the Ras pathway and beta-isoform of 14-3-3 proteins. The centre of the molecule 
contains a pleckstrin-homology (PH) domain that stimulates the exchange of 
guanidine triphosphate (GTP) for guanidine diphosphate (GDP) on Rho guanidine 
exchange factors, which in turn may activate transcription factors, for instance 
NF-kB. The C-terminus domain functions as a GTPase activating protein for 
p21rac, a small GTPase of the Ras superfamily that regulates actin polymerisation 
and the activity of an NADPH oxidase in phagocytic cells (Deininger et a/., 2000; 
Holyoake, 2001).
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1.3.1.3 Signalling pathways activated by oncogenic forms of Abl tyrosine 
Kinase
The increased tyrosine kinase activities of v-Abl and BCR/ABL, compared with 
the cellular c-Abl, correlate with their transforming activities. The molecular 
mechanisms by which these activated tyrosine kinases cause malignant 
transformation have remained obscure until the last few years, when there have 
been reports that multiple signalling pathways are activated by v-Abl and/or 
BCR/ABL (Guo et al., 1998).
v-Abl
The y-Ahl oncogene in the Abelson murine leukemia virus encodes a fusion 
protein in which a portion of retroviral Gag protein replaces the SH3 domain of c- 
Abl (Figure 1.6) (Abelson and Rabstein, 1970). Removal of the SH3 domain 
constitutively activates the tyrosine kinase, and a myristoylation site in the Gag 
moiety confers localization to the inner plasma membrane; both modifications are 
important in the transforming activity of v-Abl (Prywes et at., 1983). Infection of 
neonatal mice by the Abelson murine leukemia virus results in rapid, 100% 
fatality because of pro/preB cell tumors. Although in vitro v-Abl transforms 
pro/preB cells as well as myeloid cells and a subset of 3T3 fibroblasts (Renshaw 
et a l, 1992), in vivo it only transforms pro or preB cells, that is the early B- 
lineage cells that have partially or completely rearranged their heavy chain genes 
(Rosenberg, 1994). This striking pro/preB cell tropism for transformation, in the 
absence of any evidence of pro/preB-specific viral infection, is likely to reveal 
regulatory paths that are unique to the early B-lymphocyte lineage.
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Data from a variety of experiments show that signalling through the GTP-binding 
protein Ras is essential for transformation by v-Abl. Inhibition of p21Ras activity 
by antisense oligonucleotides, microinjection of a blocking monoclonal antibody 
to p21Ras or expression of the catalytic domain of Ras GAP all block 
transformation by v-Abl (Sawyers et al., 1995; Skorski et al., 1994; Smith et al., 
1986).
v-Abl has been shown to activate phospholipase C-mediated breakdown of 
phosphatidylcholine, generating diacylglycerol, which then activates the Protein 
Kinase C (PKC) (Owen et al., 1993). Subsequent studies showed that the v- 
Abl/PKC pathway causes an increase in &c/-Xl mRNA levels (Chen et al., 1997). 
Evidence is accumulating to support a role for JAK binding and STAT in v-Abl 
transformation. JAK-1 and JAK3 associate directly with v-Abl (Danial et ah,
1998). In v-Abl-transformed cells, STATl, STAT5 and STAT6 have been shown 
to be constitutively activated (Danial et ah, 1995). Deletion of 200 amino acids in 
the DNA-binding portion of the v-Abl C-terminus that are required for association 
with JAKl results in a mutant v-Abl which cannot provide cytokine-independent 
survival of BaF3 pro-B cells.
BCR/ABL
All BCR/ABL proteins have tyrosine kinase activities intermediate between the 
weaker c-Abl and the stronger v-Abl (Clark et ah, 1987). In vitro BCR/ABL 
expression confers growth factor independence, but is fully transforming only for 
certain cells (Raitano et ah, 1997).
BCR/ABLp210 contains the first 927 amino acids of BCR and its transforming 
ability is provided by multiple functional domains, as shown by mutating critical 
residues in Src homology 2 domain (R552L), the autophosphorylation site in the
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kinase domain (Y793F), or the GRB2 binding site (Y177). The combination of all 
three mutations blocked the antiapoptotic activities of BCR/ABL in 
haematopoietic cells (Cortez et al, 1995), while single mutations just reduced 
transformation by BCR/ABL (McWhirter and Wang, 1993; Pendergast et al., 
1993).
The first 63 amino acids of the BCR part in the fusion protein forms an a-helical 
coiled-coil structure, which leads to the oligomerisation of BCR/ABL molecules, 
autophosphorylation and activation of the catalytic activity (McWhirter et al., 
1993). This domain is also involved in the localisation of BCR/ABL by its ability 
to interact with F-actin. Whereas the c-Abl protein shuttles between the nucleus 
and the cytoplasm, due to the presence of nuclear localisation and export signals 
(NLS and NES) within its C-terminal region, the BCR/ABL fusion proteins are 
exclusively cytoplasmic. This cytoplasmic localisation of BCR/ABL seems to be 
essential for its biologic activities because BCR/ABL entrapment in the nucleus 
by leptomycin B induces apoptosis with its tyrosine kinase activities (Vigneii and 
Wang, 2001).
Basic mechanisms thought to be relevant in the pathogenesis of Ph-positive 
leukemias are activation of mitogenic signalling, inhibition of apoptosis and 
altered adhesion to stroma. BCR/ABL leads to tyrosine phosphorylation of 
multiple proteins and, therefore, simultaneous activation of multiple signalling 
pathways, but little is known about their downstream targets. A host of substrates 
can be tyrosine phosphorylated by BCR/ABL, summarised in Table 2, below. 
Most important, because of autophosphorylation, there is a marked increase of 
phosphotyrosine on BCR/ABL itself, which creates binding sites for the SH2 
domains of other proteins (Carlesso et ah, 1996; Tauchi et ah, 1997).
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Protein Function
Crkl Adapter
Crk Adapter
She Adapter
Talin Cytoskeleton/cell membrane
Paxillin Cytoskeleton/cell membrane
Fak Cytoskeleton/cell membrane
Fes Myeloid differentiation
Ras-GAP Ras-GTPase
PLCy Phospholipase
PI 3-Kinase Serine Kinase
Grb2 Adapter
Vav Haematopoieitc differentiation
Bap-1 14-3-3 protein
Table 2. Substrates of BCR/ABL.
Generally, substrates of BCR/ABL can be grouped, according to their 
physiological role, into adapter molecules, proteins associated with the 
organisation of the cytoskeleton and the cell membrane, and proteins with 
catalytic function. Some phenotypic correlations can be made with the molecular 
abnormalities:
1. Constitutive activation of the Ras pathway (via TYR177 of the BCR) 
mimicking the growth-factor-stimulation of cells, leads to a proliferative 
behavior. Expression of dominant-negative Ras in BCR/ABL expressing K562 
cells resulted in apoptotic cell death (Sakai et a l, 1994). The activation of Ras 
is dependent on SOS and Ras-GAP and, in CML cells, evidence has been 
found for constitutive Ras activation and reduced Ras-GAP activity (Skorski et 
al., 1994). The mechanism of Ras activation appears to be mediated through 
the adapter proteins GRB2 and She, which have been demonstrated to be
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associated with BCR/ABL (Skorski et ah, 1995b). The constitutive activation 
of Ras in BCR/ABL transformed cells is likely to lead to an anti-apoptotic 
pathway required, but insufficient, for transformation (Cortez et al., 1995).
2. Activation of PI 3-K/AKT as well as the JAK/STAT pathway is most likely 
responsible for the anti-apoptotic potential. There is increasing evidence that PI 
3-K is important in transformation by BCR/ABL. PI 3-K activity has been 
shown to be regulated by BCR/ABL and required for growth of CML cells, 
using antisense oligodeoxynucleotides to reduce PI 3-K expression. Further, 
wortmannin, a specific inhibitor of the pi 10 subunit of PI 3-K, was shown to 
inhibit proliferation of BCR/ABL transformed cells, but not normal 
haematopoietic cells (Calabretta and Skorski, 1996; Skorski et ah, 1995a). 
Constitutive phosphorylation of STATl and STAT5 was observed in both cells 
transformed by BCR/ABL and in Ph+ human leukemia cell lines. Using 
thermosensitive mutants this phosphorylation was shown to be directly due to 
the tyrosine kinase activity of BCR/ABL (Ilaria and Van Etten, 1996; 
Nieborowska-Skorska et al., 1999). In contrast, JAK kinases are not 
consistently activated in BCR/ABL positive cells and activation of STAT5 by 
BCR/ABL is not blocked by dominant-negative JAK2 mutants. (Carlesso et 
al., 1996; Chai et al., 1997; Ilaria and Van Etten, 1996). These data suggest 
that BCR/ABL might activate STATs by a JAK-independent pathway.
Studies have indicated that the members of the anti-apoptotic pro-apoptotic 
bcl-2 family BAD, Bcl-2 and Bcl-Xl are downstream targets of STATs. BAD, 
Bcl-2 and Bcl-XL expression restored the leukemogenic potential of a 
BCR/ABL mutant defective in transformation in 32Dcl3 cells (Cirinna et al.,
2000) and after ectopic expression of Bcl-2, 32Dcl3 cells proliferated in the 
absence of IL-3. All the three proteins have been shown to be regulated by
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STATs (Sanchez-Garcia and Grutz, 1995). BCR/ABL was shown to increase 
the transcription of Bcl-XL promotor and the protein levels through the 
STATs. Moreover, this induction was blocked by the expression of a dominant 
negative STAT5 mutant. (Gesbert and Griffin, 2000).
3. Activation of focal adhesion molecules (FAK/paxillin) via CRK-L, as well as 
an abnormal response to SDF-1, leads to adhesive and migratory abnormalities 
of leukemic cells. Studies have shown that CML cells have altered adhesion to 
marrow stromal cells and some extracellular matrix proteins, notably 
fibronectin (Gordonera/., 1987).
1.4 Aims of this thesis
It is believed that BCR-ABL activates similar intracellular signalling pathways to 
IL-3 to promote proliferation and survival in cytokine-dependent haematopoietic 
cells. Therefore, BCR/ABL might regulate the same set of genes that are 
controlled by IL-3. The identification of the abnormalities that result in cancerous 
growth can lead to the understanding of the mechanisms that control normal 
growth and development.
Major cellular effects of BCR/ABL are related to increased mitogenic activity and 
reduced sensitivity to apoptosis. BCR/ABL reduces the growth factor 
requirements of primary haematopoietic stem cells, converts IL-3-dependent 
murine haematopoietic cells lines to growth factor independence and it is 
mitogenic in fibroblasts. BCR/ABL is likely to bypass normal controls on the 
proliferation of haematopoietic cells by altering the expression of cell cycle 
regulatory proteins through aberrant activation of upstream signalling pathways.
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thus one purpose of this investigation was to identify the downstream targets and 
their physiological roles.
Although several signalling pathways have previously been reported to play 
essential roles in BCR/ABL transformation, the exact mechanism by which the 
proliferative signals transduce from BCR/ABL and IL-3 to the pRB pathway is 
not yet well defined. The second aim of this work was to determine the signalling 
pathways by which BCR/ABL and IL-3 mediate proliferation and survival in 
haematopoietic cells.
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Chapter 2. MATERIAL AND METHODS
2.1 Reagents and buffers
6x Agarose Gel Loading Buffer
0.25% (w/v) Bromophenol blue 
0.25% (w/v) Xylene cyanol 
30% (v/v) Glycerol
Ampicillin /Sigma)
A stock solution of lOOmg/ml was made in ddH^O and stored at -20°C. The final 
concentration used in 2x TY medium was lOOpig/ml.
Ix Bacteria transforming buffer 
lOOmM CaCl2
70mM MnClz
40mM Na acetate
pH adjusted to 5.5
Blotto
10% (w/v) fat-free dried milk powder reconstituted in PB ST
Doxycyclin /Sigma. UK)
Doxycyclin was added to the media at the appropriate concentration from a 
Img/ml fresh solution in ddHzO.
Ix Gilbert and Church hybridisation buffer 
7% (w/v) BSA
ImM SDS
200mM NaP0 4 pH 7 . 2
45% (v/v) Formamide
LY294002 /Calbiochem. UKl
, A stock solution of 50mM was made up in DMSG and stored at -20°C. The final 
concentration used was 50pM.
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lOx Morpholinopropanesulphonic acid (MOPS) buffer 
200mM MOPS pH 7.0
50mM Sodium acetate
lOmM EDTA
Phosphate-buffered saline (PBS)
12.5mM NaCl
2mM Na2HPÜ4
ImM NaH2P0 4 ,2 H2 0
pH adjusted to 7.2
Phosphate-buffered saline -  tween tPBSTl
0.05% (v/v) Tween20 (Polyoxyethylene-sorbitan monolaurate) in PBS
Propidium Iodide staining buffer 
0.1% (v/v) Triton X-100
0.1% (w/v) Na3QH 5 0 7 .2 H2 0  (sodium citrate)
RIPA buffer
1% (v/v) NP-40
0.5% (w/v) Sodium deoxycholate
0.1% (w/v) SDS
2 tablets Complete™ protease inhibitor cocktail (Boehringer
Mannheim) per 10ml 
Made up in PBS
RNA loading buffer
50% (v/v) Glycerol
ImM EDTA
0.4% (w/v) Bromophenol blue
0.4% (w/v) Xylene cyanol
2x SDS-PAGE loading buffer 
4% (w/v) SDS
62.5mM Tris.HCl pH 6.8
1% (v/v) Glycerol
0.01% (w/v) Bromophenol blue
10% (v/v) 2-mercaptoethanol
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lOx SDS-PAGE running buffer 
250mM Tris.base
2M Glycine
1% (w/v) SDS
lOx SDS-PAGE transfer buffer 
250mM Tris.base
2M Glycine
20x Sodium citrate-sodium chloride tSSCl 
3M NaCl
300mM Sodium citrate
pH adjusted to 7.0
STI571 (Novartisl
A stock solution of lOmM was made in distilled water and stored at 4°C. STI571
was a gift from E. Buchdunger.
Ix Tail lysis buffer
lOOmM Tris.HCl (pH 8.8)
0.02% (w/v) SDS
5mM EDTA (pH 8.0)
200mM NaCl
50x Tris-sodium acetate-EDTA fTAEl buffer 
2M Tris base
0.05M EDTA
57ml glacial acetic acid
Tris-EDTA /TEl buffer
lOmM Tris.HCl pH 7.6
ImM EDTA pH 8.0
2x TY broth
1.6% (w/v) Bacto-tryptone
1% (w/v) Yeast extract
85mM NaCl
pH adjusted to 7.4
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2.2 Enzyme Unit Definitions
Calf intestinal alkaline phosphatase fCIAP)
One unit catalyses the hydrolysis of 1 p,mol of 4-nitrophenyl phosphate per 
minute at 3TC  in IM diethanolamine, 10.9mM paranitrophenyl phosphate, 
0.5mMMgCl2(pH9.8).
Restriction endonucleases
One unit digests lp,g of phage X DNA to completion in 60 minutes at 37“C in a 
50|Li1 reaction volume.
Tag DNA polymerase
One unit incorporates lOnmol of total deoxyribonucleotides (dNTPs) into acid 
insoluble DNA in 30 minutes at 74°C under standard DNA polymerase assay 
conditions.
T4 DNA ligase
One Weiss unit of enzyme catalyzes the exchange Inmol of ^^ P from 
pyrophosphate into Norit-absorbable substance in 20 minutes at 37® C. 0.01 Weiss 
unit of ligase is equivalent to 1 ligation unit which catalyses greater than 95% 
ligation of lp,g lambda/Hindlll fragments in 20 minutes at 16® C.
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2.3 Antibodies 
Primary Antibodies
Antibody Clone Specie Dilution Source
pl6lNK4a m-156 Rabbit polyclonal 1 2000 Santa Cruz Biotechnology, Inc.
p2icipi F-5 Mouse monoclonal 1 2000 Santa Cruz Biotechnology, Inc.
p2?Kipi C-19 Rabbit polyclonal 1 2000 Santa Cruz Biotechnology, Inc.
pRB - Mouse monoclonal 1 1000 PharMingen
P-pRB Thr821 Rabbit polyclonal 1 1000 Biosource, International
P-pRB Ser807/811 Rabbit polyclonal 1:500 New England Biolabs
pl07 C-18 Rabbit polyclonal 1 2000 Santa Cruz Biotechnology, Inc.
pl30 C-20 Rabbit polyclonal 1 2000 Santa Cruz Biotechnology, Inc.
Cyclin A C-19 Rabbit polyclonal 1 2000 Santa Cruz Biotechnology, Inc.
Cyclin D2 M-20 Rabbit polyclonal 1 2000 Santa Cruz Biotechnology, Inc.
Cyclin D3 18B6-10 Rat monoclonal 1 2000 Santa Cruz Biotechnology, Inc.
Cyclin E M-20 Rabbit polyclonal 1 2000 Santa Cruz Biotechnology, Inc.
CDK2 M-2 Goat polyclonal 1 2000 Santa Cruz Biotechnology, Inc.
CDK4 C-22 Goat polyclonal 1 2000 Santa Cruz Biotechnology, Inc.
CDK6 C-21 Rabbit polyclonal 1 2000 Santa Cruz Biotechnology, Inc.
ABL Ab-3 Mouse monoclonal 1 1000 Calbiochem
AKT - Rabbit polyclonal 1 1000 New England Biolabs
P-AKT Thr308 Rabbit polyclonal 1 1000 New England Biolabs
Secondary Antibodies
Antibody Specie Dilution Source
Anti-mouse IgG Goat 1:2000 Dako
Anti-mouse IgG Goat 1:2000 Dako
Anti-mouse IgG Mouse 1:2000 Southern Biotechnology associates, Inc
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2.4 Western Immunoblotting
Protein isolation
For total cellular lysates, cell pellets were resuspended in 2 times packed cell 
volume of RIPA buffer and incubated on ice for 10 minutes. Cellular debris was 
spun down at 14,000 rpm for 10 minutes in a microfuge and the lysate was 
transferred to a fresh tube. The protein concentration was assayed using the Bio- 
Rad DC kit protein (Bio-Rad, USA).
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Fifty |Lig of whole cellular protein extracts were mixed with one volume of 2x 
SDS-PAGE loading buffer and boiled for 5 minutes prior to loading onto an SDS- 
polyacrylamide gel and separation at 40V overnight.
The gels consisted of a 4% stacking gel above a resolving gel.
Resolving gel Stacking gel
5% 12% 4%
30% (v/v) Acrylamide 5.5ml 13.3ml 3.3ml
1.5 M Tris pH 8.8 8.3ml 8.3ml -
0.5 M Tris pH 6.8 - - 6.3ml
10% SDS 0.3ml 0.3ml 0.25ml
H2O 19.0ml 11.2ml 15ml
25% (w/v) APS 0.05ml 0.05ml 0.03ml
TEMED 0.05ml 0.05ml 0.03ml
Rainbow™ marker High molecular weight range (14.300 -  220,000 Da) 
(Amersham LifeScience) was used as a size standard.
Transfer to Nitrocellulose Membrane
The resolved proteins were electrophoretically transferred on to a nitrocellulose 
membrane (Schleier and Schuell, Dassel, Germany). The transfer was performed
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in SDS-PAGE transfer buffer in the presence of 23% (v/v) ethanol at 140V for a 
minimum of 5 hours.
Immuno-detection
The membrane was blocked with blotto for 20 minutes, followed by overnight 
incubation with the primary antibody at 4°G. The membrane was then washed 
with PB ST and incubated with the appropriate secondary horseradish peroxidase- 
conjugated antibody for 20 minutes at room temperature. After extensive washing 
with PB ST the proteins were visualised using enhanced chemiluminescence 
fluorography (ECL, Amersham International, UK) and exposed to Hyperfilm™ 
MP (Amersham International, UK).
2.5 DNA preparation and Manipulation
Preparation of heat-shock competent bacteria
500ml of 2x TY was inoculated with 1ml of a fresh overnight culture of HBlOl 
bacteria strain and incubated at 37°C until the culture reached an optical density 
of 0.5 at 600nm. The cells were then chilled on ice for 2 hours, pelleted by 
centrifugation (2000g for 10 minutes) and resuspended in 250 ml of Ix bacteria 
transformation buffer. After incubation on ice for 40 minutes, the cells were 
pelleted as before and resuspended in 25ml of the transformation buffer 
containing 15% glycerol. This suspension was stored at -70°C in 200pl aliquots.
Transformation of Competent Bacteria with Plasmid DNA 
One microlitre of plasmid DNA was mixed with 40jli1 of heat-shock competent 
bacteria and incubated on ice for 5 minutes. The bacteria were then heat-shocked 
for 1 minute at 42°C and placed on ice for another 5 minutes. The bacteria were
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plated onto TY plates supplemented with ampicillin (75p,g/ml), and incubated 
overnight at 37°C.
Small Scale Preparation of Plasmid DNA from Bacteria (Miniprep)
Three ml of 2x TY were inoculated with a single colony of bacteria and grown at 
37°C for 6 hours. A 1ml sample was centrifuged at 14,000rpm in a microfuge for 
1 minute and the pellet resuspended in 300p,l of STE buffer. The proteins were 
removed by phenol : chi orof orm extraction and the DNA precipitated by the 
addition of 600p,l of 100% ethanol. After centrifugation at 14,000rpm in a 
microfuge for 5 minutes the pellet was air-dried and resuspended in 20fil H^O. 
Ten pil of the sample was digested and analysed on an agarose gel.
Large Scale Plasmid Preparation tMaxiprepl
500ml of 2x TY was inoculated with 5ml of exponentially growing culture and 
incubated overnight at 37°C. The cells were pelleted by centrifugation at 2000g 
for 5 minutes at 4°C. The plasmid DNA was purified using a Qiagen Plasmid 
Mega Kit following the manufacturer’s instructions. To eliminate any protein 
contamination, the DNA was phenol : choloroform extracted before ethanol 
precipitation.
Quantification of DNA
The concentration of DNA was determined by measuring the absorbance at 
260nm where the value of 1.0 corresponded to 5G[ig/ml of DNA. The quality of 
purified DNA was also estimated by measuring the ratio of CD 260 / CD 280 
where a value of 1.8-2.0 indicated purified DNA.
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Agarose Gel Electrophoresis
Agarose gel electrophoresis was performed in 1-1.6% (w/v) agarose (Ultra-pure 
agarose, Gibco BRL) in TAE containing lp,g/ml ethidium bromide at 5-8V/cm. 
DNA samples were prepared in Ix sample buffer.
Subcloning of DNA Fragments 
DNA digestion
Plasmids were digested using 2 units of restriction enzyme per microgram of 
DNA in the appropriate Ix restriction endonuclease buffer (New England Biolabs, 
UK). Reactions were incubated for a minimum period of 2 hours at the 
manufacturer’s recommended temperature. After electrophoresis, the fragments of 
interest were excised and purified from the agarose gel.
Dephosphorylation of vector DNA
To prevent re-ligation of linearised vectors, the 5’ phosphate groups were 
removed. 5U of CIAP was added to the restriction reaction and incubated for 30 
minutes at 37°C. The phosphatase was inactivated by incubation at 75“C for 15 
minutes.
DNA ligation
Vectors and DNA fragments were quantified by agarose gel electrophoresis and 
the ligation was set up such that the ratio of the insert:vector DNA was 3:1. A 
typical reaction consisted of the following:
150ng insert DNA
50ng vector DNA
2/rl lOx T4 DNA ligase buffer
1/xl T4 DNA ligase (400,000U/ml)
ddH2 0  to 20/xl
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The reactions were incubated overnight at room temperature. Afterwards, 
competent bacteria were transformed with the ligated DNA reaction mix and 
grown in TY media.
Phenol/Chloroform Extraction and ethanol Precipitation
DNA was mixed by vortexing with an equal volume of 
Phenol/Chloroform/Isoamyl Alcohol 25:24:1 (v/v) (SIGMA). The phases were 
separated by centrifugation at 16,000g for 5 minutes at room temperature. The 
aqueous phase was then carefully removed and transferred to a new tube and the 
DNA was precipitated by incubation on dry ice with 1/10 volume of 3M NaCl and 
2 volumes of ethanol. The DNA was collected by centrifugation at 16,000g for 10 
minutes at 4°C, The pellets were washed once in 70%(v/v) ethanol, air-dried and 
resuspended in TE.
Gel Purification of DNA Fragments
DNA fragments were separated by electrophoresis and the DNA band required 
was excised using a razor blade. The fragments were purified using the Geneclean 
n  kit (bio 101) according to the manufacturers instructions.
2.6 Northern blot
RNA extraction
Total RNA was extracted following the protocol provided with the RNeasy kit 
from Qiagen (Qiagen Ltd, UK). The concentrations were determined by 
measuring the optical density at 260nm.
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RNA electrophoresis and Northern blotting
Twenty p,g of total RNA were mixed with 15p,l of a solution of 65% (v/v) 
formamide, 22% (v/v) formaldehyde and 13% (v/v) lOx MOPS buffer. The 
samples were then heated at 70°C for 5 minutes, after which 2|xl of RNA loading 
buffer was added. The samples were loaded onto a 1.4% (w/v) agarose gel 
containing Ix MOPS buffer, 10% (v/v) formaldehyde and Ipg/ml ethidium 
bromide. The gel was run overnight at 30V in Ix MOPS buffer. The RNA was 
transferred onto a Hybond™ -XL nylon membrane using capillary transfer for 30 
hours. It was then crosslinked to the membrane by ultraviolet exposure 
(Spectrotronics Corp.) at 120mJ/cm^.
Preparation of Radiolabelled DNA probes
Fifty ng of DNA were denatured on a heating block at 100°C for 10 minutes and 
quickly chilled on ice for 5 minutes. The denatured DNA was added together with 
5|li1 of Redivue [a-^  ^P] dCTP (lOmCi/ml) to a Rediprime random primer labelling 
tube (Amersham LifeScience) and incubated at 37°C for 30 minutes. Free 
deoxynucleotides were removed by passing the probe over a Nick™ G-50 
Sephadex column. The probe was added to the pre-equilibrated column and 400pil 
of TE was used to wash the probe into the column. The probe was eluted and 
collected adding another 400jxl of TE to the column.
Hvbridisation
The Northern blot membrane was prehybridised at 65°C for 30 minutes in 
hybridisation buffer. Then hybridised overnight at 42°C with 200fxl of denatured 
labelled probe. The Northern blot was washed several times in 2x SSC, 0.2% 
(w/v) SDS, followed by washes in Ix SSC, 0.1% (w/v) SDS till the counting <10 
Bcq. The filter was exposed to auroradiograph film.
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2.7 Mammalian Cell Manipulation
Cell lines used
NAME SOURCE REFERENCE
BaF3 Dr. M. Gordon (Ormerod et al., 1992)
BaF3-p210 Dr. M. Gordon (Daley et al., 1991)
TonB210.1 Dr. G. Daley (K.M. Clucher et al., 1998)
All cells were maintained in RPMI-1640 (Gibco BRL, UK), supplemented with 
10% foetal calf serum (PCS), 2mM L-Glutamine (Gibco, BRL, UK), lOOU/ml 
Penicillin-Streptomycin (Gibco, BRL, UK) and 10% (v/v) WEHI-3B conditioned 
medium as a source of IL-3. Cells were maintained at 37°C in a humidified 
Heraeus incubator at a CO  ^ concentration of 10%.
Cryopreservation of cells
A 25 ml sample of cell culture at a density of 2x10^ cells/ml was centrifuged at 
490g for 5 minutes at 4®C, The supernatant was removed and the cell pellet was 
resuspended in 1ml freezing medium (DMSO 10% and PCS 90%). Cell aliquots 
of 1ml were transferred to screw cap freezing tubes (Nalgene), placed in a 
Nalgene cryo freezing box containing propan-2-ol, and left at -80°C for one day, 
cooling the samples at a rate of approximately 1®C per minute. Thereafter the 
ampoules were stored in liquid nitrogen.
Counting of cells.
Ten fi\ of cell suspension was added to 10/d of trypan blue (Sigma, UK), mixed 
together and then introduced to the haemocytometer chamber (Weber, UK). 
Viable cells were identified as those cells excluding the trypan blue dye.
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Transfection of Mammalian Cells 
Transient co-transfection of Baf3 cells
Cells were split 1:4 24 hours prior to transfection, resulting in a cell density of 
approximately 1.5x10^ cells/ml. Per transfection, 1x10  ^cells were spun at 490g at 
4®C for 3 minutes and resuspended in 150jil RPMI medium. Cells were 
transfected by standard electroporation (0.28 kV and 960|xF). After 
electroporation the cells were left to recover in a 37®C incubator for 20 minutes 
and then transferred to 10ml of medium and returned to the incubator. 3 hours 
after electroporation, dead cells were removed by separating through a Ficoll 
gradient (lOOOg for 30 minutes at 4®C). The DNA of interest was. cotransfected 
with spectrin-GFP as a marker for transfected cells. After 24 hours cells were 
analysed by FACS unless stated otherwise.
Stable transfection
Constructs were electroporated into BaF3 cells together with pBABE containing a 
puromycin selection marker and selected for 3 days with increasing 
concentrations of puromycin (0.5-2.0jig/ml)
Transduction o f TAT Fusion Proteins
The TAT fusion proteins TAT-p27^P^WT, TATp27^P^KK and TAT-eGFP were 
obtained from Dr. S. Thomas, Department of Haematological Medicine, Guy’s, 
King’s. St. Thomas’ School of Medicine, London. Cell lines were transduced by 
adding the appropiate TAT-protein to the medium at a final concentration of 100- 
500nM. After 24h and 48h cells were analysed by FACS.
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FACS
Propidium Iodide Staining
The cells were harvested by centrifugation at l,300rpm (Sorval RC3C) for 3 
minutes. After washing once with PBS, the cells were fixed in 90% (v/v) ethanol, 
10% (v/v) PBS overnight at 4°C. The cells were washed once with PBS and 
incubated in PI staining buffer containing lOpg/ml Rnase (SIGMA, UK) at 37°C 
for 30 minutes, followed by a second incubation of 30 minutes at 37°C in the 
presence of PI at 20pg/ml.
Annexin V
Cells were stained using the Annexin V kit (R&D, Systems Europe Ltd, Oxon, 
UK) according to the manufacturer’s instructions.
FACS analysis
Cell profile was analysed using a Becton Dickinson FACSort analyser, combined 
with the CELLQuest software. Control stained cells were used to set up the 
amplifier gains and detector voltages for the detector parameters. Using a FSC-H 
vs. SSC-H dot plot cells were selected in a gate in order to avoid clumps. 10,000 
gated events were collected and shown as a histogram of counts vs. FL2-A and 
the %G0+G1, %S and %G2/M phases were measured.
PCR
Mouse tails were digested overnight at 55°C in 500p,l of Ix Tail lysis buffer 
supplemented supplemented with proteinase K at a final concentration of 0.5 
mg/ml. After centrifugation, the supernatant was transferred to a new eppendorf 
tube and the DNA precipitated using 0.7 volumes of iso-propanol. The DNA was 
subsequently amplified by PCR using specific primers for the vector disrupting
68
the gene to detect the mutant and primers for the undisrupted gene to detect the
wild type. The hybridisation temperature varied depending on the primers used
and the quality of the DNA extracted.
A typical PCR sample contained the following:
100|Lil lOX Taq polymerase buffer (Promega)
5pl 2mM each dATP,dCTP,dGTP,dTTP
lOOfxl 25mM MgClz
lOj-il Taq polymerase (5000U/ml)
5p-l each primer (50pmol each)
5ng template DNA
Reactions were carried out in 0.5ml centrifuge tubes and overlaid with a single 
drop of mineral oil (Sigma, USA) to prevent evaporation.
The thermocycle programme was usually set for 39 amplification rounds at: 
Denaturing: 93°C 1 minute 
Annealing: 53®C 1 minute
Elongation: 72°C 1 minute 
The PCR programme was followed by a 7 minutes hybridisation extension at 
72°C.
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Chapter 3. Regulation of cell cycle regulatory proteins by BCR/ABL 
and IL-3 in haematopoietic cells.
3.1 Introduction
IL-3 was initially identified and cloned on the basis of its ability to induce 
proliferation of marrow cells in the absence of growth factors. In 1968, Noel 
Warner induced the development of a large series of primary murine tumours, 
mostly plasmacytomas, by the injection of mineral oil or pristane into responsive 
BALB/c mice (Warner et al., 1969). One of these primary animals (WEHI-3) 
appeared highly unusual in that the enlarged lymph nodes were greenish in colour. 
Analysis showed that this tumour was in fact a rare myelomonocytic leukemia 
and transplantation studies led to the derivation of four very different sublines of 
transplantable tumours (WEHI-3AD). Interestingly, cocultures of the original 
WEHI-3B tumour cells with normal marrow cells led to colony formation 
demonstrable as originating from the cultured normal cells, suggesting that the 
cell line had an unusual capacity to produce CSF. More remarkable was the 
curious appearance of the small numbers of developing colonies. These were 
composed of uniformly dispersed cells in globular clouds and of small clusters of 
giant cells. In 1973, pokeweed mitogen-stimulated spleen-conditioned medium 
(SCM) proved able to stimulate the formation of the same curious dispersed 
colonies as had developed in the earlier cocultures of marrow cells with WEHI-3B 
cells (Parker et al, 1973), and later on, its ability to stimulate multipotential and 
erythroid colony formation in cultures of mouse foetal liver cells in the absence of 
added erythropoietin was discovered (Johnson and Metcalf, 1977). In the 
following decades, numerous studies contributed to the identification and cloning 
of IL-3 (Ihle et a l, 1983; Prystowsky et al., 1984). Today, it is widely
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acknowledged that IL-3 plays an important role in regulating the proliferation, 
differentiation and survival of haematopoietic cells (Lee et al., 1982).
The biological effects of BCR/ABL have been shown to overlap with EL-3, for 
example chronic administration of EL-3, or direct expression of IL-3 in mouse 
bone marrow by retroviral gene transfer leads to a hyperplasia similar to that 
observed in the chronic phase of CML. Moreover, it has also been shown that 
progenitor CD34+ cells from some CML patients can survive and proliferate in 
vitro in the absence of exogenous growth factors (Bedi et al., 1994; Strife et al., 
1988). Similarly, the expression of p210BCR/ABL can abrogate EL-3 dependence 
in haematopoietic cell lines (Daley et al, 1988, Hariharan et al, 1988) and it is 
sufficient to induce Gl-to-S phase transition, DNA synthesis and activation of 
cyclin-dependent kinases in cells that were arrested in G1 by growth factor 
deprivation (Cortez et al, 1997). Antisense transcripts of BCR/ABL abolished 
resistance to apoptosis after IL-3 withdrawal in BaF3 cells that p210 expression 
had rendered IL-3 independent.
Although BCR/ABL has been shown to activate many signal transduction 
pathways that overlap with those induced by cytokines, including the Ras/MAPK 
(Cortez et al, 1997) and JAK/STAT pathways (Ilaria et al, 1996), the exact 
mechanism by which BCR/ABL and interleukin IL-3 promote cell proliferation 
and survival has not been established.
This chapter details the work carried out to identify the regulation of the pRB 
pathway in mediating signals from IL-3 and BCR/ABL. Experiments described in 
the first parts of the chapter were designed to identify the potential targets of IL-3 
and BCR/ABL in regulating the cell cycle progression, the mechanisms by which 
they are regulated and their roles. For this, the cell cycle profile of BCR/ABL 
expressing and non-expressing cells were analysed by FACS and the patterns
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compared. Western and Northern blot experiments were used to study the
expression and regulation of the control proteins upstream of pRB.
The final section looks into the possible upstream signalling pathways triggered 
by BCR/ABL and IL-3 to regulate cell proliferation and apoptosis.
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3.2 The use of BaF3 cells as a model
The mouse pre-B cell line BaF3 requires IL-3 to proliferate as well as to 
overcome a default apoptotic program (Palacios and Steinmetz, 1985). BCR/ABL 
has been shown to be able to protect BaF3 cells from undergoing G1 cell arrest 
and subsequent apoptosis following IL-3 withdrawal (Daley and Baltimore, 
1988). I investigated the proliferative signals derived from BCR/ABL and IL-3 in 
BaF3 cells and BaF3 cells stably expressing BCR/ABL (i.e. BaF3-p210) in the 
absence or presence of IL-3. The cells were split in fresh medium containing 10% 
(v/v) WEHI-3B conditioned medium as a source of IL-3 at a density of 1.5x10  ^
cells/ml. After 24 hours, half of each cell line was transferred to fresh media 
containing 10% (v/v) WEHI-3B conditioned medium while the other half was 
transferred to fresh media lacking the IL-3 supplement. After 24 hours the cells 
were harvested and stained for FACS analysis. Cell cycle analysis after propidium 
iodide staining (Figure 3.1) indicated that, in the presence of IL-3, both the 
parental and the BCR/ABL transformed BaF3 cells proliferated normally with no 
detectable sign of cell cycle arrest or apoptosis. In contrast, a significant 
difference was observed in the IL-3 deprived cells. The results revealed that 
following the withdrawal of IL-3, the parental BaF3 cells accumulated at the G1 
phase of the cell cycle, before undergoing apoptosis. After 24 hours, over 80% of 
the cells were arrested in Gl, and nearly all of the cells displayed detectable signs 
of apoptosis (<2N DNA content) after 72h of IL-3 depletion (Figure 3.1b). 
However, none of the BaF3-p210 cells underwent cell cycle arrest or apoptosis 
following the withdrawal of IL-3, confirming that expression of BCR/ABL could 
indeed protect BaF3 from the Gl cell cycle arrest and subsequent apoptosis 
induced by EL-3 depletion.
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a) BaF3 BaF3-p210 BaF3 BaF3-p210
IL-3
DNA content
Apoptotic 1% 1% 1% 3%
Gl
S
G2/M
84%
5%
10%
69%
19%
11%
61%
25%
13%
67%
21%
9%
b)
-IL-3
BaF3
Oh 6h 12h 24h 48h 72h
Apoptotic 1% 1% 4% 5% 40% 72%
Gl 62% 62% 81% 84% 56% 24%
S 17% 18% 7% 2% 2% 2%
G2/M 20% 19% 8% 7% 2% 1%
Figure 3.1. Effects of IL-3 and/or BCR/ABL on cell cycle progression and survival in 
BaF3 cells.
a) Cell cycle analysis of BaF3 and BaF3-p210 cells in the absence or presence 
of IL-3. Cells were cultured for 24h in the presence or absence of IL-3.
b) Cell cycle analysis of BaF3 cells after IL-3 withdrawal. Cells were harvested 
at Oh, 6h, 12h, 24h, 48h and 72h after IL-3 withdrawal.
Cell cycle progression was assessed by PI staining, as described in Chapter 2. 
The cell cycle profile is expressed as the number of cells against DNA content 
and the percentages of cells in each phase are indicated.
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3.3 The expression and regulation of the cell cycle regulatory proteins.
To identify the targets of IL-3 and BCR/ABL in mediating cell survival and 
proliferation, the expression levels of molecules along the pRB pathway were 
examined in both BaF3 and BaF3-p210 cells cultured with and without IL-3 for 
24 hours. BaF3 and BaF3-p210 cells were subjected to either 24 hours of IL-3 
deprivation or left untreated. The cells were harvested and the lysates prepared 
with RTPA lysis buffer. The lysates (50pg) were fractionated on a 5% SDS-PAGE 
gel for the detection of high molecular weight proteins, such as pRB, pl07, pl30 
and BCR/ABL, and on a 12% SDS-PAGE gel for the small proteins like cyclins 
and CDKs. Western blot analysis (Figure 3.2) showed that in IL-3 deprived BaF3 
cells, the two pocket proteins, pRB and p i07, were present in their respective 
faster migrating hypophosphorylated forms, while in the presence of IL-3 and/or 
BCR/ABL both were present at comparatively higher levels and in their 
hyperphosphorylated forms, which implies a derepression of E2F-dependent gene 
transcription and progression into S phase. In contrast, the expression of p i30 was 
down-regulated in the presence of IL-3 or BCR/ABL Next, the expression 
patterns of cyclins, CDKs and CKIs, which are known to be responsible for 
controlling pocket protein phosphorylation, were studied. In IL-3-deprived BaF3 
cells, the cyclins D2, D3, E and A were undetectable or present at very low levels, 
while their expression was detected at significant levels in the presence of IL-3 
and/or BCR/ABL. In contrast to the cyclins, no dramatic difference was observed 
in the expression levels of their kinase partners, CDK2, CDK4 and CDK6 in both 
BaF3 and BaF3-p210 cells in the presence or absence of IL-3. It was concluded 
that IL-3 and BCR/ABL signals modulate the expression of the cyclins, but not 
their kinase subunits, CDKs.
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BaF3 BaF3
IL-3 - 
BCR/ABL -
+ +  
-  +
IL-3 - 
BCR/ABL -
+ +  
-  +
BCR/ABL
(anti-ABL)
pl07
pl30
pRB
pRB (CDK4 act.) 
pRB (CDK2 act.) 
cyclin D2 
cyclin D3 
cyclin A 
cyclin E
p27^pi
p2icipi
p |^ lN K 4 a
CDK4
CDK6
CDK2
CDC2
Figure 3.2. Western blot analysis of cell cycle related proteins in BaF3 cells in the 
absence or presence of IL-3 and/or BCR/ABL.
50//g of total cell extracts from BaF3 and BaF3-p210 cells cultured with 
and without IL-3 for 24h were separated by SDS-PAGE, blotted and 
probed with the antibodies indicated above. For the detection of 
BCR/ABL, p i07, pl30 and pRB, lysates were separated on a 5% SDS- 
PAGE. For all the other proteins a 12% SDS-PAGE gel was used.
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I next investigated if the up-regulation of cyclin D and E expression was 
associated with the corresponding increases in their dependent kinase activity, 
which is responsible for pocket protein phosphorylation, using specific phospho 
pRB antibodies. pRB is the key physiological substrate for cyclin/CDKs, and 
specific sites are phosphorylated in vivo by distinct Gl/S cyclin/CDKs. Therefore, 
antibodies that specifically recognise CDK4/6 or CDK2-phosphorylated residues 
on pRB were used to monitor the in vivo D- and E-type cyclin-dependent kinase 
activity in BaF3 cells in the presence or absence of IL-3 and BCR/ABL. This 
method has considerable advantages over in vitro kinase assays, particularly for 
studying CDK4/6 activity. The results obtained with in vitro kinase assays are 
frequently inconsistent, mainly due to phosphorylation by contaminating kinases 
and changes of CDK4/6 activities under the conditions used. Moreover, the 
immunoprécipitation procedures may also alter the kinase activities of the 
complexes. In contrast, using the CDK-specific anti-pRB antibodies permits the 
monitoring of the actual in vivo kinase activity of the cyclin and dependent kinase 
complexes in their physiological environment. Two pRB phospho-specific 
antibodies were used to recognise the phosphorylated forms of pRB: anti-pRB 
(Ser807/811), which recognises the CDK4/6 kinase-phosphorylated residues 
Ser807 and Ser811 and anti-pRB (Thr812), recognising pRB only when 
phosphorylated on Thr812 by CDK2. Figure 3.2 shows that pRB is 
phosphorylated at Ser807/811 at 24 h in the presence of IL-3 and/or BCR/ABL. In 
contrast, phosphorylated forms of pRB by CDK2 were hardly detectable in cells 
expressing BCR/ABL. This result might be explained by a later activation of 
cyclin E and A kinase activity in late G1 to S, presumably as a result of up- 
regulation of the expression of their respective cyclin and kinase subunits.
Since IL-3-deprivation induced a dramatic decrease in the enzymatic activity of 
the CDKs in BaF3 cells, despite the minimal effect in their protein expression, it
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was of interest to study the expression of molecules involved in the control of the 
CDK activity. An important mechanism of inhibition of CDK activity is 
represented by the CKI superfamily, therefore their expression was examined. 
Interestingly, it was observed that only p27^^^ was up-regulated in IL-3 starved 
BaF3 cells and substantially down-regulated in the presence of IL-3 and/or 
BCR/ABL expression. another member of the Cip/Waf family of CKIs,
and a member of the INK family, were undetectable in IL-3 starved
BaF3 cells, but abundantly expressed in response to IL-3 and/or BCR/ABL. These 
results suggested that p27^^\ but neither p21 '^^  ^ nor p i6^^% plays a role in 
repressing CDK activity in the BaF3 cells when deprived of growth and survival 
signals. Since the expression of cyclin E and CDK2 were not significantly 
modulated by BCR/ABL, this finding indicated that BCR/ABL could be targeting 
p2 7 Kipi modulate the activity of cyclin E/CDK2.
The results described above indicated that ip27^^\ cyclin D2 and cyclin D3 might 
be important targets for IL-3 and BCR/ABL in regulating cell proliferation and/or 
survival. Thus, the IL-3 or BCR/ABL derived signals up-regulate cyclin D2 and 
D3 expression and down-regulate the expression level of the cyclin-dependent 
kinase inhibitor p27^^\ culminating in the induction of cyclin-dependent kinase 
activity, pocket protein hyperphosphorylation, activation of E2F activity and 
continued cell proliferation.
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3.4 Modulation of cyclin D2, cyclin D3 and p27^P^  mRNA levels.
To explore the mechanisms by which IL-3 and BCR/ABL regulate cyclin D2 and 
D3 and p27^^  ^ expression, Northern blot analyses were performed on BaF3 and 
BaF3-p210 cells in the presence or absence of IL-3 (Figure 3.3). I observed an up- 
regulation of cyclin D2 mRNA levels and a down-regulation of p27^^  ^mRNA in 
the presence of IL-3 and/or BCR/ABL expression. In a paradox with the results 
obtained at the protein level, the level of cyclin D3 mRNA was largely unchanged 
with or without IL-3, but was down-regulated in the BaF3 cells expressing 
BCR/ABL.
Collectively, these observations suggested that cyclin D2 and p27^^  ^expression in 
response to IL-3 and/or BCR/ABL are regulated, at least partially, at the 
transcriptional level. In contrast, the expression of cyclin D3 appears to be 
regulated by a different mechanism.
To discriminate possible artefacts associated with the selection of BaF3 cells 
stably expressing BCR/ABL, two different approaches were followed: firstly, a 
BaF3 cell line with tetracycline-dependent BCR/ABL expression (TonB210.1) 
was used, and secondly, BCR/ABL activity in BaF3-p210 cells was inhibited 
using the drug STI571.
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BaF3
IL-3
BCR/ABL
cyclin D2 
mRNA
cyclin D3 
mRNA
p27»pi
mRNA
28S
18S
Figure 33. Northen blot analysis of cyclin D2, cyclin D3 and p27*^ *P^  in BaF3 
cells in the absence or presence of IL-3 and/or BCR/ABL.
BaF3 and BaF3-p210 cells were cultured with and without IL-3 for 24h. 
Equal loading of total RNAs was confirmed by staining with ethidium 
bromide.
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3.5 Expression of Cyclin Ds and p27^ P^  is associated with BCR/ABL 
expression.
TonB210.1 cells are IL-3 dependent, but demonstrate IL-3 independence in the 
presence of the tetracycline analogue doxycycline (Klucher et al., 1998). This cell 
line, derived from BaF3 cells, was generated using the control elements of the 
tetracycline resistance operon encoded in TnlO of Escherichia coli to regulate 
gene expression. As a result, TonB210.1 cells express BCR/ABLp210 in response 
to the addition of doxycycline.
Initially, the TonB210.1 cells were starved of IL-3 to induce cell arrest in the G1 
phase, and 48 hours later doxycycline was added to stimulate BCR/ABL 
expression and entry in the cell cycle. Contrary to expectations, the cells did not 
progress though the cell cycle after doxycyclin stimulation. Trypan blue staining 
indicated that after 48 hours of IL-3 depletion, a large proportion of the cells was 
already dead. It is likely that the remaining population had already activated 
irreversible apoptotic pathways.
A new strategy was then designed: the cells were cultured in the absence of IL-3 
for 48 hours and treated with doxycycline to induce BCR/ABL expression at 3h, 
12h, 24h and 48 hours prior to harvesting. All the cells were collected at 48 hours 
and stained for FACS analysis. Cell cycle analysis after propidium iodide staining 
(Figure 3.4) showed that after 48 hours of IL-3 starvation, the majority of the non­
induced TonB210.1 cells accumulated at G1 phase of the cell cycle (>70%). The 
same profile was observed for those cells treated with doxycycline for both 3 and 
12 hours. However, this arrest could be partially abrogated in those cells treated 
with doxycycline for 24 hours: there was a significant reduction of cells in G1 and 
a concomitant increase of cells in S and G2/M phase. Cells stimulated for 48 
hours presented the same profile as those cultured in the presence of IL-3.
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DOX
TonB.210
Apoptotic 18% 16% 16% 14% 17%
G1 70% 70% 71% 63% 56%
S 8% 9% 8% 17% 22%
G2/M 6% 5% 5% 6% 7%
Figure 3.4. BCR/ABL expression promotes progression into cell cycle.
TonB210.1 cells were cultured in absence of IL-3 and treated with 
doxycycline (l[xg/ml) to induce BCR/ABL expression at Oh, 3h, 12h, 24h 
and 48h prior to harvesting.
Cell cycle progression was assessed by PI staining, as described in Chapter 2.
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The expression of BCR/ABL was analysed by Western blotting (Figure 3.5). The 
induction of BCR/ABL expression upon addition of doxycycline was first 
detectable by 24 hours, concurrent with the cells re-entering S and G2/M phases 
from Gl. By the same time, the expression of cyclin D2, D3 and E was induced, 
while the expression levels of their dependent-kinases, CDK4, 6 and 2, remained 
largely unchanged after the induction of BCR/ABL expression. Significantly, the 
up-regulation of the cyclin D2, D3 and E was associated with an increase in cyclin 
D -  and E-dependent kinase activity. The three pocket proteins became 
hyperphosphorylated at 24 hours, and thus decreased their mobility in SDS- 
PAGE.. Again, the expression of the CKI p27^^  ^was inversely correlated to that 
of BCR/ABL. p27^‘P^ accumulated in the absence of BCR/ABL expression, 
concomitant with cell cycle arrest and pocket protein hypophosphorylation. 
However, after 24 hours of doxycycline treatment, a dramatic down-regulation in 
p2 7 Kipi was observed.
After 48 hours, the expression of BCR/ABL reached its maximum, and was 
accompanied by an intensified up-regulation of cyclin D2 and down-regulation of 
p27^Pi, pl07 and pl30 expression and their hyperphosphorylated forms continued 
to be up-regulated, whereas pRB was present at lower levels.
These results confirm that BCR/ABL can overcome the cell cycle arrest induced 
by IL-3 withdrawal by modulating the expression of cyclin D2, D3 and p27^^\ 
The Northern blot analysis revealed that the cyclin D2 mRNA level was up- 
regulated, while the p27^^^ mRNA level was down-regulated, in response to 
BCR/ABL induction (Figure 3.6). Moreover, they showed that the kinetics of 
cyclin D2 and p27^^  ^mRNA expression correlated with those of their respective 
proteins. Consistent with the previous results, the level of cyclin D3 mRNA was 
decreased upon BCR/ABL induction.
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TonB.210.1
DOX treatment 12 24 48 h
BCR/ABL
(anti-ABL)
cyclin D2
cyclin D3
cyclin E
CDK4
CDK6
p27K:pl
pl30
pRB
CDK4/6 activity 
CDK2 activity
Figure 3.5. Effects of the induction of BCR/ABL expression cells in the 
expression of cell cycle related proteins in TonB210.1.
Cells were cultured in the absence of IL-3 for 48h and treated 
with doxycycline (Ipg/ml) to induce BCR/ABL expression at Oh, 
3h, lOh, 24h and 48h prior harvesting. 50/^g of total cell extracts 
were separated by SDS-PAGE, blotted and probed with the 
antibodies indicated above.
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mRNA
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Figure 3.6. Northen blot analysis of cyclin D2, cyclin D3 and p27*^ P* after 
induction of BCR/ABL expression in TonB210.1 cells.
Cells were cultured in the absence of IL-3 for 48h and treated 
with doxycycline (Ipg/ml) to induce BCR/ABL expression at Oh, 
3h, lOh, 24h and 48h prior to harvesting.
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3.6 Effects of the inhibition of BCR/ABL activity in BaF3-p210 cells 
using the specific inhibitor STI571
STI571, a 2-phenylaminopyrimidine derivative, has been shown to selectively 
inhibit the tyrosine kinase activity of c-ABL and BCR/ABL(Druker et ah, 1996). 
It has been demonstrated that the drug STI571 can specifically block the 
proliferation of BCR/ABL-positive cell lines and tumors and induce these cells to 
undergo apoptosis (Beran et ah, 1998; Deininger et ah, 1997). BaF3-p210 cells 
were deprived of IL-3 and treated with 25p-M STI571 for 24 hours. The cells were 
collected and both the cell cycle profiles and the expression of cell cycle 
regulatory molecules were analysed.
Inhibition of BCR/ABL with STI571 resulted in an arrest of the cells at Gl phase. 
After 24 hours of treatment with STI571, 85% of the BaF3-p210 cells were 
arrested in Gl compared to 53% for the untreated cells. Interestingly, this arrest 
was overcome by IL-3, suggesting that both molecules affect the same signalling 
pathways (Figure 3.7). In effect, cells cultured in the presence of IL-3 proliferate 
normally with no detectable sign of cell cycle arrest or apoptosis.
It is interesting to notice that, although both molecules induce cell cycle 
progression, cell proliferation was not enhanced by the combination of IL-3 and 
BCR/ABL. This lack of synergy between the molecules supports the hypothesis 
that both BCR/ABL and IL-3 activate similar signalling pathways and hence a 
threshold is imposed in their biologieal effects by the maximum activation level 
of their substrates.
Western blot results showed that the inhibition of BCR/ABL by STI571 resulted 
in a down-regulation of the expression of Cyclin D2 and D3, but induced the 
expression of p27^^  ^ (Figure 3.8). This was accompanied by the down-regulation 
of both cyclin D-CDK4/6 and cyclin E-CDK2 activity, as revealed by the specific
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anti-phospho-pRB antibodies. Consistent with previous results, the pocket 
proteins pRB and pl07 were down-regulated and hypophosphorylated following 
STI571 treatment, but the p i30 expression was induced in response to STI571. 
The Northern blot results confirmed the regulation at the transcriptional level of 
both cyclin D2 and p27^^^ (Figure 3.9). However, despite the cyclin D3 protein 
level being significantly down-regulated by STI571, the cyclin D3 mRNA level 
was not dramatically affected. This suggests that the expression of cyclin D3 is 
regulated by BCR/ABL at the post-transcriptional level.
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IL-3
BaF3-p210
+ +STI57I
(24h)
Apoptotic 2% 4% 2% 3%
Gl 53% 85% 47% 50%
S 31% 5% 38% 37%
G2/M 14% 6% 13% 10%
Figure 3.7. STI571 abrogates the BCR/ABL-mediated rescue from G l arrest in 
BaF3-p210 cells.
Cells were incubated with STI571 (25^M) for 24h in the presence or 
absence of IL-3. Cell cycle progression was assessed by PI staining as 
described in Chapter 2.
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BaF3-p210
IL-3
STI571
+
+
Cyclin D2
Cyclin D3
p2?Kipl
p2icipi
CDK6
CDK4
CDK2
pl07
pl30
pRB
CDK4/6 activity 
CDK2 activity
Figure 3.8. Effects of STI571 on the expression of cell cycle related proteins in 
BaF3-p210 cells.
Cells were incubated for 24h with STI571 (25pM) in the absence or 
presence of IL-3. 50/^g of total cell extracts were separated by SDS- 
PAGE, blotted and probed with the antibodies indicated above.
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IL-3
STI571
BaF3-p210
- +  +  
+  - +
cyclin D2 
mRNA
cyclin D3 
mRNA
p27« '^pi
mRNA
Figure 3.9. Northen blot analysis of cyclin D2, cyclin D3 and p27^ 'P^  in BaF3-p210 
cells after treatment with STI571.
Cells were incubated for 24h with STI571 (25 pM) in the absence or presence 
of IL-3. Equal loading of total RNAs was confirmed by staining with ethidium 
bromide.
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3.7 Cell cycle analysis of BaF3 and BaF3-p210 cells after 
overexpression of cyclin D2.
Having observed that the expression of cyclin D2 in BaF3 and BCR/ABL 
transformed BaF3 cells was correlated with a proliferating status, it was of interest 
to investigate whether cyclin D2 could induce cell growth and/or provide 
protection from cell death. To determine if cyclin D2 plays an important role in 
mediating proliferation and survival of these cells, I analysed whether exogenous 
expression of cyclin D2 could abolish the Gl cell cycle arrest and apoptosis 
induced by IL-3 withdrawal and STI571 treatment in BaF3 and BaF3-p210 cells, 
respectively. Stable transfectants of BaF3 and BaF3-p210 cells, constitutively 
over-expressing cyclin D2, were generated. The full-length mouse cyclin D2 
cDNA was cloned into the BamHl cloning site of the pBABE-puro expression 
vector, a plasmid containing a puromycin resistance gene. The plasmid was 
transfected into BaF3 and BaF3-p210 cells using electroporation. Cells 
transfected with the empty expression vector were used as a control.
To test the ability of cyclin D2 to induce proliferation and/or protect cells from 
apoptosis, IL-3 deprivation was used to induce apoptosis. BaF3, BaF3-p2I0 cells 
and their cyclin D2-transfected clones were cultured in the absence of IL-3 for 24 
hours. BaF3-p2I0 and BaF3-p2I0-cyclin D2 cells were additionally treated with 
25pg/ml of STI57I for the same period of time. Cell cycle analysis by PI staining 
revealed that after 24 hours of IL-3 deprivation, 82% of the BaF3 cells were 
arrested at the Gl phase of the cell cycle compared to 72% for BaF3-cyclin D2 
cells (Figure 3.10). Similarly, 72% of BaF3-p2I0 cells were arrested in Gl after 
24 hours of STI57I treatment, while the BaF3-p2I0 cells over-expressing cyclin 
D2 proliferated normally (Figure 3.11).
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a)
Apoptotic
Gl
S
G2/M
BaF3
Oh 24h 48h
1%
66%
19%
14%
3%
82%
7%
6%
40%
53%
4%
3%
b) BaF3-cyclin D2
Oh 24h 48h
Apoptotic 4% 2% 4%
Gl 68% 72% 75%
S 16% 16% 13%
G2/M 12% 10% 8%
Figure 3.10. Ectopic expression of cyclin D2 overcomes the Gl arrest and apoptosis 
induced by IL-3 withdrawal in BaF3 cells.
a) Cell cycle analysis of BaF3 cells at Oh, 24h and 48h after IL-3 withdrawal.
b) Cell cycle analysis of BaF3-cyclin D2 at Oh, 24h and 48h after IL-3 
withdrawal.
Cells cultured in the absence of IL-3 were harvested at Oh, 24h and 48h and 
analysed as described in chapter 2.
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a) BaF3-p210
STI571 Oh 24h 48h
Apoptotic 5% 11% 21%
Gl 52% 72% 67%
S 25% 9% 9%
G2/M 18% 8% 4%
b) BaF3-p210-cyclin D2
STI571 . Oh 24h 48h
Apoptotic 5 % 10% 6%
Gl 54% 50% 51%
S 21% 22% 26%
G2/M 20% 18% 17%
c) BaF3-p210
Oh 24h 48h
-  +  -  + cyclin D2-pBABE 
cyclin D2
Figure 3.11. Ectopic expression of cyclin D2 overcomes the Gl arrest and apoptosis induced by 
STI571 treatment in BaF3-p210 cells.
a) Cell cycle analysis of BaF3-p210 cells at Oh, 24h and 48h after STI571 treatment.
b) Cell cycle analysis of BaF3-p210-cyclin D2 at Oh, 24h and 48h after STI571 
treatment.
Cells were cultured in the absence of IL-3 and treated with 25pM of STI571. Cells 
were harvested at Oh, 24h and 48h and analysed as described in chapter 2.
c) The expression of cyclin D2 in BaF3-p210 cells after STI571 treatment was analysed 
by Western blotting.
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The difference between the parental cells and the cyclin D2-expressing cells 
continued and increased over the following 24 hours. After 48 hours only 7% of 
the BaF3 cells remained cycling against over 20% of the cyclin D2 transfected 
cells. Moreover, 40% of the BaF3 cells underwent apoptosis (sub-Gl phase), 
whereas only 4% of BaF3-cyclin D2 were dead. BaF3-p210 cells showed a drastic 
reduction in their proliferating population, while BaF3-p210-cyclin D2 cells 
continued to grow normally.
To verify this phenomenon further, Annexin V staining was performed in BaF3- 
p210 and BaF3-p210-cyclin D2 cells (Figure 3.12). Annexin V is an anticoagulant 
protein that preferentially binds negatively charged phospholipids. Early in the 
apoptotic process, the phospholipid asymmetry between the inner and outer 
leaflets of the plasma membrane is disrupted leading to the exposure of 
phosphatidylserine (PS) on the outer leaflet. Annexin V binding to PS is calcium 
dependent and of very high affinity. The binding of Annexin V-FITC to cells 
permits a differentiation of apoptotic cells (Annexin V positive) from non­
ap optotic cells (Annexin V negative). The data obtained confirms that ectopic 
expression of cyclin D2 can prevent the cell arrest and apoptosis induced by 
STI571 in BaF3-p210 cells.
It is interesting to notice that although both techniques revealed the ability of 
cyclin D2 to induce cell proliferation and to protect cells from apoptosis, they 
show significantly differing percentages of viable and apoptotic cells. This could 
be explained by the higher sensitivity of Annexin V staining compared to PI 
staining for the detection of apoptotic cells. Whereas Annexin V fully 
differentiates apoptotic from viable cells, analysis with propidium iodide staining 
might fail to distinguish these populations, for example early apoptotic cells 
whose DNA content has not yet decreased from 2N or cell clumps.
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BaF3-p210
Viable
Apoptotic
77%
14%
9%
87%
BaF3-p210-cyclin D2
Oh
Viable
Apoptotic
76%
12%
24h 48h
! .'S
36%
51%
40%
45%
Figure 3.12. Effects of overexpression of cyclin D2 on cell cycle progression 
and survival of BaF3-p210 cells.
BaF3-p210 and BaF3-p210-cyclin D2 cells were IL-3 deprived for 
48h. Cells were harvested at 0, 24 and 48h and stained with Annexin 
V and propidium iodide as described in chapter 2 for eell viability. 
The x-axis reflects the log Annexin V-FITC fluorescence and the y- 
axis refleets the PI fluorescenee. Viable eells are negative for both 
Annexin V and PI (lower left quadrant). Early apoptotic cells bind 
Annexin V (lower right quadrant) and late apoptotic cells also bind 
PI as a eonsequence of membrane permeabilisation (upper right 
quadrant). The percentages of viable and apoptotic cells revealed by 
FACS analysis are shown.
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To confirm that the relative resistance of cyclin-D2 transfected BaF3 and BaF3- 
p210 cells to cell death was related to the presence of cyclin D2, the expression of 
the latter was analysed by Western blotting (Figure 3.11c). The levels of cyclin 
D2 in the transfected BaF3-p210 cells remained constant during IL-3 deprivation 
and STI571 treatment. In contrast, the expression of cyclin D2 in the parental cells 
drastically decreased after 24 hours of treatment.
Under normal tissue culture conditions, BaF3 and BaF3-p210 cells stably 
transfected with pBABE-puro-cyclin D2 showed a growth advantage over the 
parental cells, suggesting that the procedure of creating stable transfectants could 
involve the selection of the best growing cells. However, this enhanced growth 
phenotype was shown to be specific for the cyclin D2 transfected cells, as the 
pBABE-puro transfected cells presented the same growing profile as the parental 
cells. To assure that the changes observed were specifically due to Cyclin D2 and 
not due to unrelated mutations in the cultured cell lines, the same experiments 
were planned in transient transfectants. Unfortunately, the transient transfection 
system was unsuitable for quantitative analysis since the BaF3 cells are very 
sensitive to electroporation and require a long period of recovery before IL-3 
removal is indicated. In addition, the low transfection efficiency will tend to mask 
the resistance to apoptosis.
The results obtained indicate that cyclin D2 is required and sufficient to induce 
cell cycle progression in BaF3 and BaF3-p210 cells.
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3.8 Expression of p27^ *^  ^induces cell cycle arrest and apoptosis in BaF3 
cells.
It was postulated that the induction of p27^^^ was sufficient to cause cell cycle 
arrest of BaF3 cells and to induce apoptosis. The initial evaluation of this 
hypothesis was undertaken by transfecting p27 '^^^ in BaF3 cells using 
electroporation. However, this method proved to be unsuitable for the analysis of 
p2 7 Kipi apoptotic effect because it was not possible to generate stable clones and 
the cell mortality in transient transfections due to either the electroporation 
process or the introduction of p27 '^^  ^ could not be distinguished. A different 
protocol was then adopted for introducing p27^^^ protein in BaF3 cells. In 1988, 
the human immunodeficiency virus (HIV) TAT protein was discovered to be able 
to cross cell membranes (Frankel and Pabo, 1988; Green and Loewenstein, 1988). 
This property has been exploited to transduce heterologous proteins into cells by 
chemically cross-linking a 36-amino acid domain of TAT to them (Fawell et al., 
1994). Cells have been shown to take up proteins fused to the 11-amino acid 
transduction domain of the (HIV) TAT protein (Nagahara et al., 1998). To 
investigate the functional significance of p27^'P\ BaF3 and BaF3-p210 cell lines 
were transduced with biologically active TAT-p27^^^  ^or with TAT-mutant p27^^  ^
(TAT-p27^P^ KK) and TAT-eGFP as controls (Nagahara et al., 1998) (Figure 
3.10). Cells incubated with TAT-eGFP and TAT-mutant p27^^^ proliferated 
normally, but the majority of the p27^P^-transduced BaF3 displayed sub-Gl (<2 
N) DNA content, indicative of apoptosis (Figure 3.13). The ability of wild-type 
p27^pi, but not mutant p27^'P\ to promote apoptosis in BaF3 cells, even in the 
presence of IL-3, was confirmed by annexin V staining (Figure 3.14). These 
observations indicated that similar to IL-3 depletion, expression of p27^^  ^alone is 
sufficient to induce apoptosis in BaF3 cells. The propidium iodide staining also 
showed that the TAT p27^P^-transduced BaF3-p210 cells ceased growth and
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accumulated in G l, whereas control cells multiplied normally. Interestingly, only 
low levels of apoptosis were detected in these cells expressing BCR-ABL (Figure 
3.13). The presence of TAT-p27^P^ fusion proteins in the BaF3 and BaF3-p210 
cells was confirmed by Western blotting for p27^^  ^protein (Figure 3.13b).
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a)
48h
BaF3 BaF3-p210
TAT-eGFP TAT-p27 mut TAT-p27 WT TAT-eGFP TAT-p27 mut TAT-p27 WT
Apoptotic 2% 2% 41% 3% 5% 12%
Gl 71% 65% 44% 69% 64% 73%
S 17% 20% 9% 19% 20% 6%
G2/M 10% 13% 6% 9% 11% 9%
b) BaF3 BaF3-p210
TAT-p27^‘Pi
Figure 3.13. Effects of overexpression of p27^ *P^  on cell cycle progression and survival 
on BaF3 and BaF3-p210 cells.
Cells were transduced with TAT-eGFP, TAT-p27 (KK mutant) or TAT-p27 
WT for 48h.
a) Cell cycle progression was assessed by propridium iodide staining as 
described in Chapter 2.
b) The expression of TAT-p27 proteins was monitored by immunoblotting.
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TAT-eGFP
78%
19%
TAT-p27 mut TAT-p27 WT
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85%
13%
19%
80%
Viable
Apoptotic
TAT-eGFP
80%
19%
BaF3-p210
TAT-p27 mut TAT-p27 WT
83%
15%
65%
34%
Figure 3.14. Effects of overexpression of p27*^ ‘P* on cell cycle progression and 
survival on BaF3 and BaF3-p210 cells.
Cells were transduced with TAT-eGFP, TAT-p27^‘P^ (KK mutant) 
or TAT-p27^P^ WT for 48h. Cells were harvested at Oh, 24h and 48h 
and stained with Annexin V and propidium iodide as described in 
chapter 2 for cell viability. The percentages of viable and apoptotic 
cells revealed by FACS analysis are shown.
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3.9 Regulation by phophatidyI-inositol-3 Kinase (PI 3-K)
Since IL-3 stimulates a cascade of membrane and cytoplasmic protein 
phosphorylation, it was hypothesised that abrogation of IL-3-dependence in BaF3 
cells by BCR/ABL might result from phosphorylation and activation of the same 
proteins involved in IL-3 signal transduction. Having established cyclin D2, D3 
and p27^P^ as important targets of BCR/ABL and IL-3, I tried to identify the 
pathway involved in the transduction of the signal between BCR/ABL and its 
downstream effectors.
Both MAPKinase and PI 3-K pathways are known to be active in BCR/ABL 
transformed cells and can be interrupted by specific inhibitors. PI 3-K is involved 
in a variety of cellular responses, including cell growth, survival, metabolism, 
differentiation and membrane trafficking (Leevers et al., 1999). Various 
downstream mediators of PI 3-Kinase activity have been identified (Cross et al., 
1995; Franke et al., 1995). Among them, the serine/threonine kinase AKT (also 
referred as PKB) is thought to have a role in proliferative and anti-apoptotic cell 
responses (Dudek et al., 1997). AKT is encoded by the Akt proto-oncogene and is 
defined by a NH2 terminal regulatory domain of protein-protein interaction that 
contains a PH domain (Marte and Downward, 1997). Previous studies have shown 
that the activity of AKT is regulated directly by products of PI 3-K that bind to 
the AKT PH domain (Franke et al., 1997; Klippel et al., 1997). AKT has been 
shown to activate the p70 ribosomal protein S6 (p70^^^) and suppress the pro- 
apoptotic function of the Bcl2 family member BAD (Datta et al., 1997; del Peso 
et al., 1997), the protease caspase 9 (Cardone et a l, 1998) and the FH family 
member FKHRLl (Brunet et al., 1999: del Peso et al., 1999). Upon activation by 
extracellular signals, primarily in a PI 3K-dependent manner, AKT translocates to 
the plasma membrane and binds through its PH domain to the lipid products of PI
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3-K. Once in the plasma, AKT is fully activated by phosphorylation at specific 
residues (Marte and Downward, 1997). Two major phosphorylation sites have 
been identified: the threonine 308 and serine 473 (Meier et al., 1997).
Western blots performed in BaF3 and BaF3-p210 cells in presence or absence of 
lL-3 showed a correlation between the phosphorylation of AKT and the presence 
of lL-3 and/or the expression of BCR/ABL (Figure 3.15). Using an activation 
specific-antibody which recognises the Thr308 phosphorylated kinase-active form 
of AKT, it was observed that AKT is constitutively activated under condition of 
lL-3 deprivation in BaF3-p210 cells. Also, activation of AKT was induced by 
BCR/ABL expression in Tonb210 cells. These results suggest that modulation of 
D type cyclins and p27^^  ^protein levels may occur through constitutive activation 
of the PI 3-Kinase pathway. To investigate the potential role of PI 3-Kinase in 
mediating BCR/ABL signals, the effects of a specific inhibitor of the PI 3-Kinase 
activity, LY294002, on BaF3 cells and BaF3-P cells were studied. FACS analysis 
after 24 hours of treatment showed a clear arrest in G1 for both BaF3 and BaF3- 
p210 cells, independent of the presence of lL-3 (Figure 3.16). The same data were 
obtained using another specific inhibitor of PI 3-K, wortmannin, which is 
structurally unrelated to LY294002 (data not shown). Western blot results confirm 
the down-regulation of cyclin D2 and the up-regulation of p27^^^ in BaF3-p210 
cells after 24 hours of treatment with LY294002 (Figure 3.17). Interestingly, no 
major difference was observed in the expression of cyclin D3, suggesting that 
cyclin D3 levels may be regulated, at least partially, through another pathway or 
further downstream on the same signalling pathway. The expression of CDK4 and 
CDK6 was not affected by LY294002 treatment. Consistent with previous results, 
pl07 was down-regulated while p i30 expression was induced in response to 
LY294002. LY294002 treatment resulted in a dephosphorylation of AKT whilst 
total levels remained constant.
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IL-3
BCR/ABL
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BaF3
- - "F 4-
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- ----- — ' AKT
—  ---------- P-AKT
TonB.210.1
0 3 10 24 48 h
— • BCR/ABL
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Figure 3.15. AKT is activated in response to BCR/ABL.
The expression of total AKT and its phosphorylated form was analysed 
by western blotting.
a) BaF3 and BaF3-p210 cells cultured with and without IL-3 for 24h.
b) TonB201.1 cells cultured in absence of IL-3 for 48h and treated with 
doxycycline (Ipg/ml) to induce BCR/ABL expression, at Oh, 3h, lOh, 
24h and 48h prior harvesting.
The lysates (50pg) were fractionated on a 10% SDS-PAGE gel and 
immunoblotted with the antibodies indicated above.
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Figure 3.16. PI 3-K inhibitor LY294002 induces cell cycle arrest in BaF3 and BaF3-p210 
cells.
Cells were incubated for 24h with LY294002 (50|iM) in the presence or absence 
of IL-3. Cells were harvested and the cell cycle progression was assessed by 
propidium iodide staining as described in chapter 2.
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Figure 3.17. Effects of LY294002 on the expression of cell cycle regulators in 
BaF3-p210 cells
Ceils were incubated for 24h with LY294002 in the presence or absence 
of IL-3. 50/tg of total cell extracts were separated by SDS-PAGE, 
blotted and probed with the antibodies indicated above.
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In contrast, phosphorylation of MAPKinase was induced by LY294002, 
suggesting that PI 3-Kinase has a role in transducing the growth and survival 
signals derived from IL-3 and BCR/ABL.
The proliferation arrest induced by LY294002 in BaF3-p210 cells could be 
abrogated by overexpression of cyclin D2. Indeed, after treatment with LY294002 
for 24 hours, cyclin D2 stable transfectants were found to proliferate normally 
with no sign of cell cycle arrest or apoptosis (Figure 3.18). As expected, the 
control transfectants harbouring the empty expression vector accumulated at the 
G1 phase of the cell cycle. This result provides further evidence that cyclin D2 is 
a crucial component of signal transduction pathways downstream from 
BCR/ABL. Furthermore, these results also imply that cyclin D2 expression is 
important for cell cycle progression and survival.
Taken together, these results demonstrate that the regulation of cyclin Ds and 
p2 7 Kipi -g ^nediated, at least partially, via the PI 3-Kinase pathway.
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Figure 3.18. Expression of cyclin D2 overcomes the G1 arrest induced by 
LY294002 in BaF3-p210 cells.
Cells were incubated for 24h with LY294002 (50[iM) in the absence 
of IL-3 and analysed by FACS as described in chapter 2.
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Chapter 4. DISCUSSION
The passage of eukaryotic cells through the cell cycle is a highly regulated 
process involving ordered expression of a series of cell cycle control genes (Paggi 
et ah, 1996; Weinberg, 1995). In haematopoietic cells growth factors, such as 
interleukin 3 (IL-3), are required to induce commitment of responsive cells to 
enter the S phase but are not again necessary until the next G1 phase (Reed, 
1997). Deprivation of growth factors causes arrest in G1 (Reed, 1997), often 
followed by apoptosis (Dexter and Heyworth, 1994; Williams et ah, 1990). 
Although much is known about the growth factors of myeloid cells, their 
receptors and the initial events of signalling, the exact mechanisms and 
downstream targets which mediate the mitogenic and anti-apoptotic functions of 
cytokines remain unclear.
Numerous studies have shown that altered expression of cell cycle regulatory 
proteins through aberrant activation of intracellular signalling pathways is 
involved in the pathogenesis of various types of malignancies. BCR/ABL has 
been shown to be one of a select group of oncogenes that is capable of both 
inhibiting apoptosis and deregulating cell proliferation (Daley and Baltimore, 
1988; Daley et ah, 1990). It is believed that BCR/ABL activates similar 
intracellular signalling pathways to IL-3 to promote proliferation and survival in 
cytokine-dependent haematopoietic cells. Expression of BCR/ABL activates 
multiple signalling cascades (Cortez et ah, 1995), including the Ras (Skorski et 
ah, 1994), phosphatidylinositol 3-kinase (Skorski gr ah, 1997; Skorski et ah, 
1995a) and JAK/STAT pathways (Gesbert and Griffin, 2000), which have also 
been implicated in IL-3-dependent signalling (Coffer et ah, 1998a; Coffer et ah, 
1998b; Reddy et ah, 2000). To elucidate the molecular mechanisms and 
downstream effectors involved in normal and oncogene-induced growth and
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survival, the expression levels of molecules along the pRB pathway were studied 
in the IL-3-dependent pre-B cell line, BaF3, and in a BaF3 cell line stably 
expressing BCR/ABL, BaF3-p210.
Both IL-3 withdrawal and inhibition of BCR/ABL activity by STI571 treatment in 
BaF3 and BaF3-p210 cells, respectively, resulted in G1 arrest. This G1 arrest was 
associated with the appearance of dephosphorylated pRB, indicating an arrest at 
the G1 restriction point. In agreement with this notion was the finding that the 
cyclin D- and E-dependent kinase activities were reduced after IL-3 withdrawal or 
BCR/ABL inhibition. In order to address the mechanism by which the reduction 
in kinase activity of these complexes occurs, the expression of the cyclins, CDKs 
and CKIs was analysed. The results demonstrated that IL-3 and BCR/ABL 
promote haematopoietic cell proliferation and survival through modulation of 
cyclin D2 and p27^^^ expression. Also, they suggest that this regulation occurs 
through the PI3-Kinase pathway.
The expression of cyclin D2 and D3 is induced by IL-3 and BCR/ABL
In haematopoietic cells, the D cyclins are particularly attractive candidates for 
growth regulatory proteins, since a number of studies have emphasised the 
significance of D cyclins in growth regulation of these cells. Deregulated 
expression of cyclin D1 has been shown to be oncogenic for lymphoid cells 
(Rosenberg et ah, 1993; Withers et ah, 1991) and in primary human T 
lymphocytes the expression of cyclin D2 and D3 is IL-2 dependent and inducible 
in G1 by various mitogens (Ajchenbaum et ah, 1993). The results obtained in this 
study suggest that the cyclin Ds are downstream targets of both BCR/ABL and 
IL-3. Specifically, it was shown that IL-3 withdrawal induced the down- 
regulation of cyclin D2 and D3, in BaF3 cells. In contrast, in BCR/ABL
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expressing cells the cyclin Ds were expressed at high level independently of IL-3 
presence. To ensure that the properties observed in the BaF3 cells stably 
expressing BCR/ABL are related to BCR/ABL expression and not a result of 
mutations introduced during the establishment of the BaF3-p210 cell line, the 
findings were corroborated by two different approaches. First, a BaF3 cell line 
with tetracycline-dependent BCR/ABL expression (TonB210.1) was used, and 
second, BCR/ABL activity in BaF3-p210 cells was inhibited using the drug 
STI571. Results from both systems confirmed that the expression of cyclin Ds is 
associated with BCR/ABL expression in BaF3 cells.
At the molecular level, accumulation of cyclin Ds and down-regulation of p27^^  ^
in response to IL-3 and/or BCR/ABL expression is associated with the activation 
of CDK4/CDK6 and CDK2 activity and the phosphorylation of the pocket 
proteins. The Western blot results confirm the induction of cyclin D and E- 
dependent kinase activity, represented by hyperphosphorylated pRB (see Figures 
3.2, 3.5 and 3.7), in response to IL-3 and/or BCR/ABL, indicating a release of 
sequestered transcription factors of the E2F family and entry into S phase. Since 
cyclin D2 is the first G1 cyclin detected in proliferating BaF3 cells, the finding 
that its expression level parallels the accumulation of the in vivo CDK4/6 activity 
and pocket protein hyperphosphorylation strongly suggested that cyclin D2- 
CDK4/6 mediates the initial and continuous hyperphosphorylation of pRB during 
Gl. In addition, since CDK4 and 6 are constitutively expressed in B-lymphocytes, 
these results also indicate that cyclin D2 protein expression could be rate-limiting 
for cyclin D-CDK4/6 activity and, therefore, the initiation of pocket protein 
phosphorylation.
It is interesting to notice that although both IL-3 and BCR/ABL appear to target 
the expression of cyclin D2 and p27^^  ^ to regulate cell growth and survival, there 
are considerable differences in the expression levels of certain proteins along the
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pRB pathway (Figure 3.2). The primary consequence of cyclin D2 down- 
regulation is the reduction in CDK4/6 kinase activity. This can be followed by a 
redistribution of p27^''^ from cyclin D2/CDK4/6 complexes to cyclin E/CDK2, 
also inhibiting CDK2 activity. In BCR/ABL expressing cells, a pronounced 
reduction of cyclin D2-associated kinase activity (CDK4/6), compared to the 
parental cell line levels, was observed, suggesting a down-regulation in cyclin D2 
protein levels. However, the levels of cyclin D2 were equivalent in both cell 
lines, indicating that BCR/ABL fully restored the expression of cyclin D2. A 
possible explanation for this discrepancy could be that the role of cyclin D2 in 
these cells is not only CDK activation but also the binding of CDK inhibitors, 
such as p27^^\ It has been proposed that cyclin Ds can have a role as competitors 
for p27^^  ^binding (Bouchard et aL, 1999; Perez-Roger et al, 1999). In response 
to activation of myc, levels of both cyclin D2 and cyclin D2/CDK4-p27^'^^ 
complexes strongly increase, which accounts for a dissociation of p27^‘^  ^ from 
CDK2. However, in the cells expressing BCR/ABL, p27^^^ levels were almost 
undetectable, whilst still present at a basal level in the parental cell line in the 
presence of IL-3.
Hence, cyclin D2 could be fulfilling other roles, rather than sequestering p27^^\ 
in the BCR/ABL expressing cells. The first hypothesis is that cyclin D2 
accelerates p27*^ '^  ^ degradation by dissociating p27 '^^  ^ from cyclin E/CDK2 
complexes. Phosphorylation of p27 '^^  ^ by CDK2/Cyclin E has been widely 
observed (Muller et al., 1997; Vlach et al, 1997) and this phosphorylation results 
in subsequent degradation by the proteasome pathway. Cyclin D2 competing with 
cyclin E/CDK2 complexes for p27 '^^  ^ binding, after p27^^  ^ phosphorylation by 
cyclin E/CDK2, could increase p27 '^^  ^ turnover by hastening dissociation of 
phosphorylated p27^^  ^from cyclin E/CDK2 complexes, and thus, releasing it for 
degradation by the ubiquitin/proteasome pathway.
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The other hypothesis involves cyclin D2 targeting degradation of p27 '^^  ^ by 
phosphorylation. Other p27 '^^  ^ kinases (different from CDK2/cyclin E) can 
phosphorylate p27^ **’^  protein and regulate its inhibiting activity and/or its 
stability. For example, the Kaposis’s sarcoma-associated human herpesvirus 8 
(KSHV/HHV8) encodes a protein closely related to cellular D-type cyclins. 
Complexes formed between the viral cyclin and CDK6 can phosphorylate p27^^  ^
and trigger its degradation (Ellis et ah, 1999). In BCR/ABL expressing cells 
cyclin D2 could play a more active role directly phosphorylating p27^^\ leading 
to its ubiquitination and subsequent degradation by the proteasome.
Nevertheless, both of the hypotheses described above seem unlikely since there is 
no evidence documenting these alternative roles for cyclin D2. Therefore the 
lower levels of phosphorylated pRB in the BCR/ABL expressing cells cannot be 
attributed to a decrease in cyclin D2 associated activity, and thus another 
mechanism must be responsible. It is probable that the lower levels of substrate 
result in lower levels of phosphorylated pRB. In effect, the levels of total pRB are 
down-regulated in BCR/ABL expressing cells (Figure 3.2), even in the presence 
of EL-3.This suggests first, that pRB levels are negatively regulated by BCR/ABL, 
and second, that BCR/ABL mimics EL-3 only partially and consequently other 
signalling pathways are involved.
The essential role of cyclin D2 for cell cycle progression is documented by the 
fact that overexpression of cyclin D2 in BaF3 cells prevented the cell cycle arrest 
as well as the associated apoptosis caused by EL-3 withdrawal. Similarly, BaF3- 
p210 cells exposed to STI57I can be rescued for cell cycle progression by 
overexpression of cyclin D2. Using both PI and Annexin V staining, it was 
demonstrated that ectopic expression of cyclin D2 protects the BaF3-p210 cells 
from undergoing the Gl cell cycle arrest and subsequent cell death induced by 
STI571 treatment. This finding implies that cyclin D2 has a role in regulating cell
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cycle progression and in cell survival in these haematopoietic cells and that its 
down-regulation is crucial to the growth arrest and apoptosis. This idea is 
supported by a recent report showing that the forced expression of another D-type 
cyclin, cyclin D3, can overcome the proliferation arrest and apoptosis induced by 
activaiion of T-cell receptors in leukemic T cells (Boonen et aL, 1999).
Since the regulation of growth and differentiation of haematopoietic cells by 
cytokines involves a careful balance of proliferation and cell death, BCR/ABL 
targeting cyclin D2 and inducing its anti-apoptotic effects could disrupt the ability 
of IL-3 to control cell proliferation and viability. In normal haematopoietic cells, 
the level of cyclin D2 expression and activity is directly dependent on the level of 
IL-3. As BCR/ABL activity is constitutive, the effect is analogous to constant 
activation by IL-3. This could explain why leukemic cells expressing BCR/ABL 
have a growth and survival advantage.
expression is regulated by BCR/ABL and IL-3
Deregulation of cell cycle checkpoints is an almost universal abnormality in 
human cancers and is most often due to loss-of-function mutations of tumour 
suppressor genes such as Rb, p53 or pl6. In this study I demonstrated that 
BCR/ABL inhibits the expression of a key cell cycle inhibitor, p27^^\ p27*^ ^^  is a 
member of a family of cell cycle regulatory proteins that include p2I '^^^ and 
p5 7 Kip2 p2 7 Kipi jg ^ widely expressed inhibitor of the essential cell cycle kinase 
CDK2, which regulates entry into S phase (Hsieh et at., 2000). High levels of 
p 2 7 Kipi the activity of the CDK2-cyclin E complex and prevent
phosphorylation of critical target molecules necessary for initiation of S phase, 
including Rb. Phosphorylation of Rb is necessary for release of sequestered 
transcription factors of the E2F family and induction of E2F-dependent gene
113
expression (Dyson, 1998). In normal cells, progression through Gl/S phase 
requires p27^^^ to be displaced from CDK2, either by sequestration in cyclin D- 
CDK4 complexes, which are not inhibited by p27^^  ^(Reynisdottir et ah, 1995), or 
by down-regulation of the protein through multiple mechanisms. Extensive 
studies during the past years provided compelling evidence that p27*^ '^  ^ has a 
critical role in carcinogenesis, since p27^^^-deficient and hemizygote mice 
develop spontaneous tumours (Eero et aL, 1996). Moreover, in human tumours 
the levels of p27^‘^  ^ protein strongly correlate with prognosis (Esposito et aL, 
1997).
In the studies reported here, expression of BCR/ABL was shown to specifically 
and rapidly decrease expression of p27^^\ coincident with progression from Gl 
into S phase. The down-regulation of p27 '^^  ^ was shown to be consequent on 
BCR/ABL activity using two different approaches, that were also used to 
investigate cyclin D2 regulation, above. First, induction of BCR/ABL by a 
tetracycline-regulated promoter was associated with a down-regulation of p27^^\ 
Second, inhibition of BCR/ABL kinase activity with the ABL tyrosine kinase 
inhibitor STI571 specifically increased p27^^  ^levels.
To examine the functional significance of p27^^^ up-regulation in BaF3 cells, 
biologically active p27 '^^  ^ was transduced into BaF3 cells using a TAT-fusion 
protein. The results showed that forced expression of p27*^ ^^  is sufficient to induce 
cell cycle arrest and apoptosis in BaF3 cells. Moreover, acute overexpression of 
p2 7 Kipi i^ihibited the proliferation of BCR/ABL positive cells, indicating that 
BCR/ABL induced transformation is dependent on the level of p27^^^ protein. It 
is notable that only the wild type, but not a mutant p27^^\ which cannot interact 
with CDK2, can promote cell cycle arrest and apoptosis in BaF3 and BaF3-p210 
cells, indicating that the ability of p27^^  ^ to bind and inhibit CDK2 is important 
for mediating cell cycle arrest and apoptosis.These results support the notion that
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might function as a tumour suppressor gene not only because it works as a 
negative regulator of cell cycle progression, but also because it is associated with 
the induction of apoptosis.
Molecular mechanisms of cyclin D2, D3 andp27 '^^  ^regulation of expression
Northern blot analysis revealed that the expression of both cyclin D2 and p27^^  ^
in response to EL-3 and/or BCR/ABL are, at least partially, regulated at the 
transcriptional level. In contrast, the expression of cyclin D3 appeared to be 
regulated predominantly at a post-transcriptional level.
Although cyclin D3 protein levels were induced by BCR/ABL and IL-3, the levels 
of cyclin D3 mRNA seemed to be independent of IL-3 stimulation and were 
strongly down-regulated upon BCR/ABL expression. This paradox suggests that 
both IL-3 and BCR/ABL regulate the expression of cyclin D3 at the post- 
transcriptional level, but the regulation is achieved using different mechanisms. A 
rapid increase in the translation of cyclin D3 may be essential for the positive 
regulation of the protein expression in response to either IL-3 or BCR/ABL. 
Alternatively, regulation of the half-life of the protein, by protein stabilisation or 
decreased degradation, could be important for the accumulation of cyclin D3 in 
the absence of increased transcription. However, further studies will be needed to 
prove this notion conclusively.
The mechanism of down-regulation of p27^^^ is likely to be of interest. p27^^  ^
protein expression level is known to be regulated by several mechanisms, 
including degradation by the ubiquitin/proteasome pathway (Esposito et aL,
1997), phosphorylation (Vlach et aL, 1997) and subcellular compartmentalisation 
(Orend er flZ., 1998).
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Although most studies have shown that expression is mainly regulated at
the post-transcriptional level by controlling degradation of this protein (Hengst 
and Reed, 1996; Vlach et aL, 1997), a small number of studies have implied that 
p27^p^ might also be regulated at the transcriptional level (Dijkers et aL, 2000; 
Medema et al, 2000). Interestingly, the latter study has proposed a mechanism 
involving PI 3-Kinase-mediated inactivation of Forkhead transcription factors by 
phosphorylation. The Forkhead transcription factors AFX, FKHR, and FKHR-Ll 
are orthologues of DAF-I6 of Caenorhabditis elegans and have previously been 
shown to be involved in regulating viability and Gl to S progression (Kenyon et 
aL, 1993; Ogg et aL, 1997). AFX and FKHR-Ll have been shown to up-regulate 
p2 7 Kipi pj-Qjjioter activity (Dijkers et aL, 2000; Medema et aL, 2000). The 
Forkhead factors are exported from the nucleus in response to an AKT-dependent 
phosphorylation, thus suggesting the model that transcription of p27 '^^  ^ is 
decreased when AKT, or a kinase regulated by AKT, phosphorylates one or more 
Forkhead transcription factors.
In contrast, recent work has shown that BCR/ABL promotes degradation of 
p2 7 Kipi jjij-Qugh a proteasome-dependent degradation pathway (Gesbert et aL, 
2000; Jonuleit et aL, 2000). Proteasome-dependent degradation of other proteins 
has also been shown to be important for BCR/ABL transformation (Dai et aL,
1998). During progression through the cell cycle, p27 '^^^ is known to be 
phosphorylated by cyclin E/CDK2 complexes (Vlach et aL, 1997) on Thr-187, 
which targets this CDK inhibitor for degradation via the ubiquitin/proteasome 
pathway. Lactacystin, a cell permeable proteasome inhibitor, completely 
prevented the BCR/ABL-mediated p27 '^^  ^ down-regulation in BaF3 cells, 
implying that BCR/ABL interferes with an ubiquitin regulated proteasomal 
degradation pathway of the p27^^  ^ protein (Jonuleit et aL, 2000). Similar results 
were obtained using a different proteasome inhibitor, V-acetyl-leucyl-leucine
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norleucinal (Gesbert et al., 2000). These data are consistent with previous 
findings showing that cyclin D/CDK4/6 activity can activate cyclin E expression 
via E2F (Geng et al., 1999; Hurford et al., 1997; Lukas et al., 1997) and that 
phosphorylation of p27 '^^^ by the induced cyclin E/CDK2 results in its 
degradation via the ubiquitin/proteasome pathway (Vlach et al., 1997). It is 
therefore conceivable that expression of cyclin D2 induces down-regulation of 
p2 7 Kipi j^^ j-ough stimulation of cyclin E synthesis rates and thus cyclin E-CDK2 
activity.
Although a down-regulation of p27 '^^  ^ mRNA levels was observed in cells 
expressing BCR/ABL, this down-regulation was not as pronounced as the down- 
regulation at the protein levels and cannot account for the dramatic reduction of 
protein. In other cell systems, p27^^  ^regulation has been shown to occur at both 
transcriptional and post-trancriptional levels (Servant et aL, 2000). p27^^  ^down- 
regulation by BCR/ABL may therefore involve both down-regulation of its 
mRNA and an enhanced degradation of the protein by the ubiquitin/proteasome 
pathway.
Cyclin D2 and p27^ ^^  ^ expression are regulated through a PI 3-K-dependent 
pathway
Although BCR/ABL is known to have prominent growth promoting effects, the 
pathways involved in its ability to activate mitogenic signalling are unclear. 
Having established cyclin D2 and p27^^  ^ as important targets of BCR/ABL and 
IL-3,1 next tried to identify the pathways that are activated leading to cyclin D2 
and p27^^  ^regulation. Various signal transduction pathways have been shown to 
be activated by IL-3 and BCR/ABL, aniongst them the Ras/Mitogen-activated 
protein Kinase (MAPKinase), JAK/STAT and the PI 3-Kinase pathways.
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A potential role for PI 3-K in mediating the proliferative response (targeting 
cyclin D2 and p27^^^) from IL-3 and BCR/ABL was suggested by the observation 
that the expression of BCR/ABL resulted in an increase of phosphorylation of the 
serine/threonine kinase AKT. AKT is thought to have a role in proliferative and 
anti-apoptotic cell responses by regulating the activity of several proapoptotic 
proteins (Marte and Downward, 1997), for example BAD (Datta et ah, 1997), the 
protease caspase 9 (Cardone et ah, 1998) and FKHR-Ll (Brunet et aL, 1999). 
AKT is activated by IL-3 in a PI 3-Kinase-dependent manner (del Peso et aL, 
1997; Franke et aL, 1995). To explore this idea, the effect of the PI 3-K inhibitor 
LY294002 in BaF3 and BaF3-p210 cells in the presence or absence of IL-3 were 
analysed. Inhibition of PI 3-Kinase activity was found to induce apoptosis in both 
BaF3 and BaF3-p210 cells, and this was associated with down-regulation of 
cyclin D2 levels and up-regulation of p27^^  ^expression.
The PI 3-K enzyme is a heterodimer composed of a 110-kDa catalytic subunit and 
an 85-kDa regulatory subunit containing two SH2 domains (N- and C-terminal) 
and one SH3 domain (Kapeller and Cantley, 1994). Activation of PI 3-K by many 
growth factor receptors involves recruitment of the enzyme to the membrane 
through binding of one or both of the SH2 domains to specific pYXXM (pY, 
phosphorylated tyrosine) motifs in the receptor or in phosphorylated adapter 
molecules. There is abundant evidence that PI 3-K is activated in cells expressing 
BCR/ABL (Jain et aL, 1997; Varticovski et aL, 1991) and that this activation is 
important for BCR/ABL transformation. Previously, Skorski et al. (1997) have 
investigated the role of the PI 3-Kinase in mediating BCR/ABL-induced cell 
growth and survival by using anti sense oligonucleotides and the PI 3-K inhibitor 
wortmannin. They have reported that BCR/ABL can neither induce cell 
proliferation nor survival when PI 3-K is inhibited. Furthermore, they showed 
that one of the targets of PI 3-K, the AKT kinase, was likely to be involved in
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BCR/ABL transformation, since dominant negative mutants of AKT also 
inhibited BCR/ABL-induced transformation in vitro and in vivo.
The results obtained in this study indicate that cyclin D2 and p27^‘^  ^ are 
downstream targets of PI 3-K, in accordance with other reports recently 
published: Gesbert et al. (2000), propose that BCR/ABL activates AKT through 
PI 3-K, resulting in a significant down-regulation of p27^^  ^ and accelerated entry 
into S phase. p27^ '"'^  expression was suppressed in BaF3 cells by an activated 
mutant of AKT (AKT fused to a membrane-targeting sequence, HA-AKT -C A AX, 
whereas overexpression of a non-activated AKT (HA-AKT) had no effect. These 
results showed that activation of AKT by itself was capable of regulating p27^^  ^
levels. The same results were obtained in cells exposed to LY-294002 to block PI 
3-K activity, indicating that AKT functions downstream of PI 3-K. 
Simultaneously, another team used cells expressing temperature sensitive 
BCR/ABL to prove down-regulation of p27^^^ by BCR/ABL via PI 3-Kinase in 
BaF3 cells and human M07 cells (Jonuleit et al., 2000).
The results presented in this study suggest that BCR/ABL acts as a positive 
regulator for the PI 3-Kinase/AKT signalling pathway, which controls and co­
ordinates two major cellular processes: cell cycle progression and cell death.
Hypothetical model
Overall, the studies reported here describe a new signalling pathway for 
BCR/ABL and IL-3 to promote cell survival and proliferation. The regulation of 
cyclin D2 and p27 '^^  ^ through PI 3-K and AKT is likely to be a significant 
component of this activity.
A simple model of this signalling pathway is presented below, based on the 
integration of the results obtained in this study and published research. However,
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as mentioned previously, IL-3 and BCR/ABL do not induce identical responses, 
therefore alternative signalling pathways might be used by either molecule to 
promote cell survival and proliferation.
BCR/ABL IL-3
Cyclin D2
PI 3-Kinase
Phosphorylation
AKT
T/a/?sc/7pho/?
Phospho/y/al/o/?
Nuclear exclusion
FKHR-L1
p27
Figure 4.1. A model of BCR/ABL and IL-3 signalling.
Although PI 3-K is known to be activated by v-abl and BCR/ABL (Varticovski et 
aL, 1991), the mechanism remains unclear since abrogation of the interaction 
between BCR/ABL and p85 PI 3-K does not impair PI 3-Kinase activation or 
BCR/ABL induced growth factor independence of haematopoietic cells (Jain et 
aL, 1996). Using cells expressing mutant, temperature-sensitive p210 BCR/ABL
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in which the tyrosine in the YXXM motif of p210 BCR/abl was replaced by 
histidine it was demonstrated that abolition of the binding of BCR/ABL to p85 
SH2 was not required for BCR/ABL-induced activation of PI 3-Kinase. Despite 
the lack of direct interaction with p85 SH2 domains, expression of ts p210 
BCR/abl resulted in rapid, time-dependent activation of total and membrane- 
associated PI 3-kinase and increased PI 3-kinase activity in anti-P-tyr and anti-abl 
immunoprecipitates. Therefore, regulation of PI 3-Kinase activity by BCR/ABL 
might involve interaction with other tyrosine phosphorylated intermediate 
proteins. Significantly, activation of the kinase activity in BCR/ABL leads to 
phosphorylation of several intracellular substrates, including She, CRKL and 
pl20cbl.
CRKL is a 39kDa SH2, SH3 domain-containing adapter protein related to the 
CRK oncogene of the avian sarcoma virus, CTIO. c-CBL (Casitas B-lineage 
Lymphoma) is the cellular homolog of v-CBL, the transforming protein of the 
CAS NS-I retrovirus which can directly cause myeloid and lymphoid leukemias 
in mice (Langdon et aL, 1989). p210cbl is involved in signal transduction 
pathways in normal cells associated with proliferation or activation. For example, 
p210cbl is a common substrate of tyrosine kinases activated after haematopoietic 
cytokine receptor stimulation (Sattler et aL, 1996).
It has been proposed that a multimeric complex of signalling proteins including 
cbl, crkl or crk, and grb2 links BCR/ABL to the PI 3-Kinase pathway (Figure 
4.2). In BCR/ABL transformed BaF3 cells, cbl is a major tyrosine phosphorylated 
protein, and tyrosine phosphorylation of cbl leads to an increase in association 
with grb2 and p85 PI 3-K. Moreover, this association resulted in enhanced PI 3- 
Kinase activity (Jain et aL, 1997). Immunoprecipitates from BCR/ABL 
transformed cell lines contained the p85 subunit of PI 3-Kinase and the adapter 
proteins CRKL and CRK. In vitro binding studies indicated that the SH2 domains
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of CRKL bind directly to cbl, while the SH3 domains bind to BCR/ABL (Sattler 
et al., 1996). Altogether, these results permit to establish a model for the 
activation of PI 3-K by BCR/ABL.
Downstream proteins recruited by PI 3-K upon stimulation by BCR/ABL include 
AKT. The involvement of PI 3-K in regulating AKT was initially suspected 
following observations that the activation of AKT induced by growth factors was 
inhibited by wortmannin, a chemical inhibitor of PI 3-Kinase (Franke et al.,
1995), and also by the expression of a dominant-negative form of PI 3-Kinase 
regulatory subunit, Ap85 (Burgehng and Coffer, 1995). The regulation of AKT by 
PI 3-Kinase was confirmed afterwards: synthesis of constitutively activated forms 
of PI 3-Kinase resulted in stimulation of AKT (Franke et al., 1995; Klippel et al.,
1996). The essential role of AKT in mediating BCR/ABL leukemogenesis was 
established both in vitro and in vivo by experiments demonstrating that a 
dominant-negative Akt mutant inhibited BCR/ABL induced transformation of 
bone marrow cells and suppressed leukemia development in mice (Skorski et al.,
1997).
Similarly, IL-3 has been shown to activate the AKT kinase through a PI 3-Kinase- 
dependent pathway (Coffer et al., 1998b). Stimulation with IL-3 increased AKT 
activity and was inhibited by wortmannin and LY294002, two chemical inhibitors 
of PI 3-K activity, in the lymphoid progenitor cell line FL5.I2 (del Peso et al., 
1997). Dominant-negative mutants of AKT specifically block AKT activation by 
IL-3 and interfere with IL-3-dependent proliferation. Moreover, overexpression of 
AKT or oncogenic v-akt protects 32D cells from apoptosis induced by IL-3 
withdrawal (Songyang et al., 1997).
c-myc has been identified as a potential target of AKT and PI 3-K (Skorski et al., 
1997). Interestingly, overexpression of myc in BaF3 cells is sufficient to induce 
progression through the cell cycle (Ahmed et al., 1997) and BCR/ABL
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transformation seems to require overexpression of c-myc, since a dominant- 
negative c-Myc blocks transformation by BCR/ABL (Sawyers et aL, 1992). 
Moreover, BCR/ABL has been shown to upregulate c-Myc at the transcriptional 
level (Cortez et aL, 1995; Pendergast et aL, 1993; Stewart et aL, 1995).
The proto-oncogene c-myc is a key regulator of cell cycle proliferation and 
apoptosis. Myc is rapidly induced by growth factors and prevents exit from the 
cell cycle, c-myc has long been implicated in the pathogenesis of B-lineage 
neoplasia, notably Burkitt lymphoma in humans, plasmacytoma in the mouse and 
immunocytoma in the rat (Klein and Klein, 1986; Magrath, 1990). c-myc encodes 
a basic helix-loop-helix leucine zipper transcription factor that dimerises with 
Max and binds to specific sequences on DNA, called E-boxes (Henriksson and 
Luscher, 1996). Myc represents a potential candidate to mediate the signal from 
AKT to cyclin D2, since the expression of cyclin D2 has been shown to be 
directly regulated by Myc. The cyclin D2 promoter is repressed by Mad-Max 
complexes and de-repressed by Myc via a single highly conserved E-box element 
(Jun et aL, 1997).
The induction of cyclin D2 by Myc has been shown to contribute to cell cycle 
progression and sequestration of p27 '^^  ^ (Bouchard et aL, 1999; Perez-Roger et 
aL, 1999). In response to activation of Myc, levels of cyclin D2 and cyclin D2- 
p2 7 Kipi complexes strongly increased. Furthermore, Myc has been shown to 
abrogate the growth arrest induced by p27^^  ^by preventing association of p27^^  ^
with cyclin E/CDK2 (Vlach et aL, 1996).
After induction by Myc, cyclin D2 could directly stimulate cell progression by 
phosphorylation of pRB. Also, cyclin D2 could inhibit activity by either
dissociation of p27*^ ^^  from CDK2/cyclin E complexes, or induction of cyclin E 
expression and consequent phosphorylation and degradation of p27^ *^  ^ by the 
ubiquitin/proteasome pathway (Muller cr aZ., 1997).
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In parallel, the regulation of could occur at the transcriptional level. The
Forkhead factors FKHR-Ll and AFX, are targets of signalling by AKT (Brunet et 
ah, 1999; del Peso et al., 1999; Kops and Burgering, 2000) and have been shown 
to modulate cytokine-dependent transcriptional regulation of p27^^  ^(Figure 4.2) 
(Dijkers et al., 2000; Medema et al., 2000). lL-3 stimulation in BaF3 cells results 
in a rapid transient phosphorylation of endogenous FKHR-Ll, that can be
OV-
abrogated by inhibition of PI 3-kinase by LY294002. As a result of its 
phosphorylation, FKHR-Ll is translocated from the nucleus to the cytoplasm and 
its transcriptional activity is abolished.
Similar models of action have been proposed for cytokines in different systems. 
For example, the PI 3-K/AKT pathway has been proposed to be crucial for 
proliferation in lL-2 signalling system. Ahmed et al. (1997) demonstrated that IL- 
2 stimulates progression through the cell cycle and inhibits apoptosis in BaF3 
cells through activation of AKT, which in turn induces the expression of c-myc. 
More recently, the IFN-a has been shown to induce rapid phosphorylation of both 
AKT and its substrate FKHR to promote cell survival in primary B-lymphocytes 
(Ruuth et al., 2001). In addition, IFN-a stimulation of anti-lgM activated cells 
resulted in down-regulated expression of p27^'^\ Another cytokine that can 
promote cell survival through PI 3-K-mediated activation of AKT is the Tumor 
Necrosis Factor (TNF). Pastorino et al. (1999) demonstrated that, under no 
cytotoxic conditions, the TNF acts as other growth factors. They showed that TNF 
induces phosphorylation of the proapoptotic protein BAD and its subsequent 
translocation from the mitochondria to the cytosol to promote cell survival 
through PI 3-Kinase-mediated activation of AKT.
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The results suggest that the functional substitution of IL-3 by BCR/ABL is due to 
the constitutive activation of proteins involved in IL-3 signal transduction, and 
that PI 3-Kinase is essential for cell survival and proliferation. However, there are 
differences in the effects induced by IL-3 and BCR/ABL, for example the down- 
regulation of pRB and p27 '^^  ^ protein levels by BCR/ABL, which indicate that 
there are additional signalling pathways involved, and that they are not identical. 
As summarised at the beginning of this chapter several other pathways of cellular 
regulation are activated by IL-3 and BCR/ABL, It is likely that BCR/ABL and EL- 
3 exert their full growth-promoting activities through the simultaneous activation 
of multiple downstream signalling pathways and that these pathways interact. The 
relative importance of the signalling pathway seems to depend on the cellular 
context, what could explain the number of controversial publications on the role 
of different pathways in cell survival and proliferation. In several cases, the 
individual inhibition of each pathway is not sufficient to completely abrogate 
cytokine mediated cell survival, suggesting that cooperation between the 
pathways is required.
According with this hypothesis, a recent publication suggests a cooperation 
between the PI 3-K and STAT5 pathways to promote EL-3 mediated suppression 
of apoptosis in BaF3 cells. Rosa Santos et al. (2000), showed that the individual 
inhibition of STATS or PI 3-Kinase weakly affected the IL-3-dependent survival 
in BaF3 cells. However, the simultaneous inhibition of STATS and PI 3-K 
activities reduced the IL-3 dependent survival of BaF3. In addition, they found an 
interaction between STATS and the p8S subunit of the PI 3-Kinase after IL-3 
stimulation. In summary, they propose that IL-3 induces the coordinated 
activation of distinct signalling pathways that are involved in cell survival by 
regulating the proper balance between pro- versus anti-apoptotic molecules . 
Among the other pathways suggested to be involved in both IL-3 and BCR/ABL
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signalling is Ras. Ras is a critical signal mediator as a potent suppressor of 
apoptosis. It has been shown to be activated in response to IL-3 stimulation in 
BaF3 cells (Satoh et al., 1991). However, in a later study it was demonstrated that 
although the Ras-dependent pathway is likely to play an important role to 
facilitate the proliferation, it is dispensable for IL-3-induced growth stimulation 
(Terada et al., 1995). Analogously, BCR/ABL has been shown to inhibit 
apoptosis through activation of a Ras-dependent signalling pathway (Cortez et al.,
1996). Ras could induce the activation of PI 3-K since the latter has been 
proposed to be a direct target of Ras in other systems (Kauffmann-Zeh et al., 
1997; Marte et al., 1997).
In summary, it is conceivable that several pathways play important roles to 
facilitate proliferation although they may not be essential for IL-3 or BCR/ABL- 
stimulated antiapoptotic signal transduction.
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